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ABSTRACT 
 
The thesis work deals with the development of cryopreservation strategy for long term storage 
of MSCs and MSCs seeded tissue engineered constructs using non toxic cryoprotective agents 
as freezing medium. In the first phase, different freezing medium consisting of a combination 
of natural extracellular cryoprotectants namely trehalose, hydroxyl ethyl starch, polyvinyl 
pyrolidine and intracellular CPAs like erythritol, taurine and ectoin were used for 
cryopreservation of MNCs following the Taguchi Orthogonal Array method. Among the 
various combinations, freezing medium consisting of trehalose (0.05mM), ectoin (0.10mM) 
and catalase (100µg/ml) has shown maximum MNCs viability. These CPAs were further 
investigated individually as well as in combination to see their effectiveness towards long 
term preservation of MSCs. Among the freezing solutions, solution prepared using trehalose 
(0.3mM), ectoin (0.3mM), and catalase (100µg/ml) was found to be the most effective in 
preserving MSCs in long term basis. The viability of MSCs (73%) is found to be higher than 
the viability achieved with 10% (v/v) Me2SO (61%) used as control. The apoptotic study has 
indicated that the addition of general caspase and calpain inhibitors can reduce the apoptosis 
rate upto 10-15% thereby achieving increased cell viability of 80%. The optimum condition 
for the controlled rate freezing of MSCs was established as prenucleation cooling rate -
1
o
C/min, nucleation temperature -7.5
o
C, cold spike -80
o
C/min, post nucleation holding time 
5min, post nucleation cooling rate -1
o
C/min,  cell density (3×10
6
/ml/cell) and storage 
temperature (-150°C ) using the most effective freezing medium achieving cell viability of 
85%. The developed freezing medium has also shown its ability to preserve MSCs seeded 
tissue engineered construct. The maximum viability of 80% achieved at optimum controlled 
rate freezing of TECs was established as cooling rate -1
o
C/min, nucleation temperature -7.5OC 
and freezing medium consisting of  trehalose (0.3mM), ectoin (0.3mM), catalase (100µg/ml) 
in presence of caspase (50µg) and calpain (50µg) inhibitors. Overall, it is demonstrated that 
the developed freezing medium may pave the way for long term preservation of MSCs and 
also MSCs seeded scaffold. 
Keywords: Cryopreservation, scaffold, caspase inhibitors, trehalose, ectoin, tissue engineered 
constructs, control rate freezer 
3 | P a g e  
 
 
LIST OF CONTENTS 
 
Certificate           i 
Acknowledgement        ii 
Abstract          iii 
Contents          iv 
List of Figures          vii 
List of tables         viii 
List of abbreviations        ix 
 
 
CHAPTER I: General Introduction      1-12 
1.1. Background         1 
1.2  Preservation techniques for cells & Tissues    2 
1.2.1 Mechanical freezers       2 
1.2.2  Liquid nitrogen storage vessels     2 
1.2.3  Controlled rate freezers       3 
1.2.4  Vitrification         3 
1.2.5  Sterling engines       3 
1.3 Cryopreservation of cells and tissue     4 
1.3.1 Principle of Cryopreservation      4 
1.3.2 History of cryopreservation      4 
1.4  Important factors involved in cryopreservation                                    5 
1.4.1 Ice formation in a cell suspension       5 
1.4.2 Rate of cooling and warming        5 
1.5 Cryoprotectants        6 
1.5.1. Membrane-permeating CPA      7 
1.5.2. Non-permeating cryoprotectants     8 
1.5.1 Cryoprotectant and toxicity       8 
                  
1.6 Stem cells         9 
1.6.1 Types of stem cells        9 
1.6.2 Application of stem cells      10 
1.6.3 Mesenchymal stem cells: For tissue engineering   10 
1.6.4 Stem cell preservation      11 
1.6.5 Cryopreservation of Tissue engineering constructs   11 
 
 
4 | P a g e  
 
1.7 Cryopreservation of Tissue Engineering Construct   11 
Chapter II: Literature review       13-30 
2.1 Preservation of MSCs       13 
 
2.1.1  Alternative cryoprotectant for preserving MSCs   13 
2.1.2  Use of antioxidants and inhibitors as additive in freezing medium   15 
2.2 Cryopreservation of TECs       18 
2.2.1 Controlled Rate Freezing of TECs      20 
2.2.2 Vitrification of TECs        20 
2.3 Cryopreservation induced cell death     22 
2.3.1 Modes of Cell Death       23 
2.3.2 Apoptosis        23 
2.3.3 Extrinsic and Intrinsic pathway     24 
2.3.4  Necrosis and autophagy      27 
 2.3.5   Motivation for Cryopreservation     29 
Chapter III:  Scope and objective      31-34 
   
Chapter IV: Materials and Methods     35-49 
4.1  Chemicals and culture media        36 
 4.1.1 Cryoprotective agents 36 
 4.1.2 Antioxidants and inhibitors      36 
 4.1.3 Cell culture media and antibodies     36 
4.2  Collection and processing of umbilical cord blood    37 
4.3  Isolation and culture of MNCs       37 
4.4  Sorting and culturing of MSCs      37 
4.5  Characterization of cells       38 
 4.5.1  Morphological Characterisation     38 
 4.5.2  Immunophenotypic characterisation     38 
4.6  Cryopreservation of cells       38 
 4.6.1  Preparation of cryopreservation solution    38 
 4.6.2  Cryopreservation experiments      39 
 4.6.3  Thawing and post-thaw culturing     39 
 4.6.4  Cell viability assay       40 
 4.6.5  Cell proliferation assay        40 
 4.6.6  MTT assay        40 
 4.6.7  Apoptotic assay       40 
 4.6.8  Mitochondrial membrane potential assay    41 
5 | P a g e  
 
 4.6.9  Differentiation potential      41 
 4.6.10  CFU-F assay        42 
 4.6.11  Cell cycle analysis       42 
4.6.12  Western blotting       42 
4.6.13  Optimization of cryopreservation parameters    43 
4.7  Cryopreservation of TECs       43 
4.7.1  Preparation of scaffolds        43 
4.7.2 Formation of TECs       44 
4.7.3 Preparation of cryopreservation solutions    44 
4.7.4  Cryopreservation experiment      44 
4.8.4  Characterization of TECs      45 
4.8.4.1 Cell morphology by SEM     45 
4.8.4.2  Cell viability       45 
4.8.4.3  Cell metabolic activity      46 
4.8.4.4  Cytoskeleton analysis by confocal microscopy   46 
4.8.4.4  Osteo-induction assessment     46 
4.8.4.4  Alkaline phosphatase activity     46 
4.8.4.5  Histological study      47 
4.8.4.6  Osteogenic-speciﬁc gene Expression    47 
4.8.4.7  Mechanical strength      48 
 
Chapter V: Results and Discussion      50-66 
 
5.1 A preliminary study on cryopreservation of MNCs: selection of 
  non-toxic CPAs         52 
5.1.1 Isolation and culture MNCs      52 
5.1.2 Cell morphology study       52 
5.1.3 Cryopreservation solution      56 
5.1.4 Cell viability and apoptosis study     56 
5.1.5 Statistical analysis       59 
5.1.6 Analysis of Variance (ANOVA)     59 
5.1.7 Cell morphology analysis of cryopreserved cells   61 
5.1.8 MTT assay        62 
5.1.9 Post-thaw cytoskeleton assessment     63 
   5.1.10 Morphological analysis of cryopreserved MNCs 65 
5.1.11 Conclusion 66 
 
 
5.2  Cryopreservation of MSCs using freezing medium prepared from  
  non-toxic CPAs        68 
         
6 | P a g e  
 
5.2.1  Sorting of MSCs       68 
5.2.2  Cell morphology study       70 
5.2.3  Immunophenotypic Characterization of MSCs    71 
5.2.4  Effect of CPA composition on post-thaw MSCs viability  74 
5.2.5 Effect of Me2SO on cryopreservation of MSCs    75 
5.2.6  MTT Assay        75 
5.2.7  Post-thaw phenotyping of cryopreserved MSCs   76 
5.2.8  Change in growth curve (population doubling) in    77 
    cryopreserved MSCs       77 
5.2.9  Change of mitochondrial membrane potential in    
cryopreserved MSCs       78 
5.2.10  Cytoskeleton analysis of post-thawed MSCs    80 
5.2.11  Effect of storage duration on cell viability    82 
5.2.12  Effect of cryopreservation on differentiation     
 potential of hMSCs       85 
5.2.13  Effect of cryopreservation on clonogenic potential 
of MSCs        87 
5.2.14  Study on apoptosis pathways in cryopreserved  
induced cell death of MSCs      88 
5.2.14.1 Post thaw cell viability     89 
5.2.14.2 Caspase-mediated apoptotic signaling pathways  89 
5.2.14.3 Western blotting analysis of caspase proteins  92 
5.2.14.4 Mitochondrial membrane potential    93 
5.2.14.5 Calpain activity      94 
5.2.14.6 Western blotting analysis for calpain protein   97 
5.2.14.7 Effect of calpain inhibitor on mitochondrial     
 membrane potential and DNA Degradation   97 
5.2.15 Optimization of Controlled rate freezing parameters   
  for cryopreservation of hMSCs using T30E30C100 
   freezing medium      98 
5.2.15.1 Effect of cooling profile on MSCs viability   98 
5.2.15.2 Effect of cell density      101 
5.2.15.3 Effect of storage temperature during cryopreservation 102 
5.2.15.4 Verification of cryopreservation protocol   103 
5.2.15.4.1 The effect on the MSCs cytoskeleton and mitochondria distribution 
after cryopreservation     103 
5.2.15.4.2 Cell cycle analysis      105 
 
5.3 Cryopreservation of hMSCs seeded silk nanofibers based tissue 
engineered constructs       107 
7 | P a g e  
 
 
5.3.1  Structural integrity and cell morphology in TECs 108 
5.3.2  MSCs viability 111 
5.3.3  Proliferation assay 112 
5.3.4  Cytoskeleton analysis 113 
5.3.5  Alkaline Phosphatase activity 115 
5.3.6   Effect of cryopreservation on Mechanical properties   
   of TECs 116 
5.3.7  Calcium deposition 117 
5.3.8  Expression of osteogenic-speciﬁc genes 118 
5.3.9  Optimization of controlled rate freezing parameters for  
   preservation of TECs using T30E30C100 
    freezing medium 120 
5.3.9.1 Effect of cooling rate on MSCs viability in TECs 120 
5.3.9.2 The effects of seeding temperature on the cell viability 120 
5.3.9.3 Cell Morphology 121 
 
Chapter V: Summary and Conclusion     124-127 
Bibliography          128-151 
List of Publications         152-153 
 
 
 
 
 
 
 
 
 
 
 
 
8 | P a g e  
 
LIST OF FIGURES 
Sl. no. Figure caption Page 
no. 
Figure 1 Graphical presentation of two distinctive apoptosis pathways namely 
intrinsic pathways and extrinsic pathways. 
26 
Figure 2 Mediators of apoptosis during cryopreservation and the effective 
apoptosis inhibitors 
29 
Figure 3 Control rate setup for cryopreservation of MSCs, (A) controlled rate 
freezer and (B) vapor phase storage tank 
39 
Figure 4 Control rate setup for cryopreservation of MSCs seeded SF scaffold, 
(A) controlled rate freezer and (B) vapor phase storage tank. 
45 
Figure 5 Collection of Cord blood: (A) clamped and cut the cord just after the 
birth of baby, (B) and (C) needle is inserted in umbilical cord with 
collection bag, (D) cord blood allowed to ﬁll the collection bag by 
gravity.  
53 
Figure 6 Schematic representation of isolation procedure of MNC from 
umbilical derived cord blood 
54 
Figure 7  Cell morphology within 7 days after initial culturing 55 
Figure 8 Images show dot plots of cryopreserved and non-cryopreserved MNCs   59 
Figure 9 Illustrates S/N ratio averages for each parameter at three levels.  60 
Figure 10 Conformity test for best obtained level with the respective factor  62 
Figure 11 MTT assay of post-thawed MNCs cryopreserved in different 
compositions of extracellular cryoprotectant, intracellular, antioxidant 
and FBS.  
63 
Figure 12 Growth and attachment of cryopreserved MNCs after 48 hrs of 
incubation 
64 
Figure 13 SEM images of UCB derived MNCs  65 
Figure14 Schematic representation of isolation procedure of MNCs from 
umbilical derived cord blood 
69 
Figure 15 Phase contrast microscopy images showing morphological 
characteristics of cultured hMSCs    
70 
Figure 16 Flowcytometric analysis on the expression of MSC markers CD90, 
CD105, CD44, and CD73 as well as hematopoietic markers CD34, 
72 
9 | P a g e  
 
HLA-DR and CD45  
Figure 17 Immnuoﬂuorescence observation of passage 4 post thaw MSCs 73 
Figure 18 Effect of CPA composition on cell viability 74 
Figure 19 MTT assay of post-thawed MSCs cryopreserved in different 
compositions of extracellular cryoprotectant, intracellular, antioxidant 
with and without Me2SO  
76 
Figure 20 Culture growth curves of post thaw hMSCs with different composition 
of Trehalose, ectoin, and catalase  
77 
Figure 21: Analysis of mitochondrial membrane potential (ΔΨ m) of post thaw 
MSCs.  
79-
80 
Figure 22 F-actin morphology and distribution in cryopreserved hMSCs  81 
Figure 23 Cytometric analysis of MSCs apoptosis performed using 7AAD and 
annexin.   
84 
Figure 24 Representative phase contrast images of differentiated hMSCs.  86 
Figure 25 Effect of cryopreservation on CFU-F ability of MSCs.  87 
Figure 26 Effects of cryopreservation on cell viability in presence of caspase and 
calpain inhibitors 
89 
Figure 27   Effect of caspase inhibitors on cryopreserved-induced apoptosis of 
MSCs  
91 
Figure 28 Effect of cryopreservation on activation of caspase and Bid proteins.  93 
Figure 29 Effect of caspase inhibition on cryopreserved-induced mitochondrial 
membrane potential and DNA degradation in MSCs after 24 hrs of 
post thaw 
94 
Figure 30 Effect of calpain inhibitors (PD 150606) on cryopreserved-induced 
apoptosis. 
95 
Figure 31 Effect of cryopreservation on activation of µ-calpain 96 
Figure 32 Effect of calpain inhibition on cryopreserved-induced mitochondria 
membrane potential and DNA degradation in MSCs after 24 h of post 
thaw  
97 
Figure 33 Percentage recovery of MSCs after cryopreservation in controlled rate 
freezer under different cooling variables. 
100 
Figure 34 Temperature profile of cryochamber and sample with time 101 
10 | P a g e  
 
Figure 35 Effect of cell concentration during cryopreservation on cell viability.  102 
Figure 36 Effect of different storage temperature of cryopreserved MSCs on cell 
viability 
103 
Figure 37 Fluorescence image of F-actin and mitochondria distribution in fresh 
and cryopreserved hMSCs. 
104 
Figure 38 Cell cycle analysis of (A) non-cryopreserved MSCs and (B) 
Cryopreserved MSCs with T30/E30/C100 
105 
Figure 39 SEM images of (A) Precryopreserved scaffold  and (B) cryopreserved 
scaffold 
109 
Figure 40 SEM images of cryopreserved scaffold  110 
Figure 41 Cell viability after 24h of post thaw TECs in different freezing 
solution  
111 
Figure 42 MTT assay of the metabolic activities of post thaw MSCs in SF 
scaffolds 
112 
Figure 43 Confocal images of cytoskeleton of MSCs in cryopreserved and non 
cryopreserved TECs. 
114 
Figure 44 ALP activity of post thawed MSCs in TECs on 1, 7, 14 and 21days 
culture.  
127 
Figure 45 Ultimate tensile strength of TECs under three different conditions. 128 
Figure 46 Optical images of alizarin red staining for calcium deposition of 
osteogenically induced MSCs in post thaw TECs 
129 
Figure 47 SEM and EDX analysis of post-thaw TECs cultured in osteogenic 
differentiation medium for 21 days 
130 
Figure 48 Osteogenic gene expression levels of post thaw MSCs in TECs 
cultured in osteogenic media 
131 
Figure 49 Effect of different cooling rate on MSCs seeded TECs 132 
Figure 50 Effect of seeding temperature on MSCs seeded TECs  133 
Figure 51 SEM images of silk-nanofiber TECs under different cooling rate  134 
 
LIST OF TABLE  
11 | P a g e  
 
 
 
 
 
 
 
 
 
Sl. no. Table caption Pag
e no. 
 
Table 1 Factors influencing cryopreservation of TEC 21  
Table .2 Cryopreservation of tissue engineering constructs by vitrification 
as reported 
23  
Table 3 The specific primers for RT-PCR 47  
Table 4 Taguchi L9 array for nine cryoprotectant solutions with different 
compositions 
56  
Table 5 S/N ratio and percentage of cells in Q3 quadrant (viable cell) 57  
Table 6 ANOVA analysis of experiments consider in Taguchi orthogonal 
array 
61  
Table 7 Effect of Me2SO as an additive in freezing solution on cell viability 75  
Table 8 Immunophenotypic characterisation of MSCs after cryopreservation 77  
Table 9 Population doubling time of MSCs 78  
Table 10 Effect of storage time on MSCs viability 83  
Table 11 Comparison of cell viability of cryopreserved MSCs in T30E30C100 
solutions and Me2SO after 12months of storage 
106  
12 | P a g e  
 
LIST OF ABBREVIATION 
 
  
ADP    Adenosine diphosphate  
ASC     AT derived Stromal Cells 
AIF    Apoptosis inducing factor  
Apo3L   Apo3 ligand  
Apo2L   Apo2 ligand  
Apaf-1    Apoptotic protease activating factor 1 
BAG    BCL2 associated athanogene  
BA    Bongkrekic acid IAPs  
BAD    BCL2 antagonist of cell death  
BAK    BCL2 antagonist killer 1  
BAX    Bcl-2–associated X protein  
Bcl-w    BCL2 like 2 protein  
Bcl-x    BCL2 like 1  
βME          β-mercaptoethanol 
BM-MSCs        Bone Marrow derived MSCs 
BIK    BCL2 interacting killer 
Bcl-XL   BCL2 related protein, long isoform         
Bcl-XS   BCL2 related protein, short isoform         
Bcl-2    B-cell lymphoma 2  
BIM    BCL2 interacting protein BIM  
BNIP3   BCL2/adenovirus  
BSA         Bovine Serum Albumin 
13 | P a g e  
 
CAD    Caspase-activated deoxyribonuclease 
Caspase c  Cysteinyl aspartic acid-protease 
CD          Cluster of Differentiation 
c-FLIP    Cellular form of FLICE-inhibitory protein 
CFU-F         Fibroblast Colony Forming Unit 
CIDOCD    Cryopreservation-induced, delayed-onset cell death 
C100                     Catalase 100µg 
CPDA        Citrate Phosphate Dextrose Adenine 
CB         Cord Blood 
dATP    Deoxyadenosine triphosphate  
DD    Death domain  
D10    10% v/v Dimethyl sulfoxide 
DR3    Death receptor 3 
DR4    Death receptor 4 
DR5    Death receptor 5 
DISC    Death-inducing signaling complex 
DNA    Deoxyribonucleic acid 
DMEM-LG        Dulbecco’s modified Eagle’s media-low glucose 
EndoG    Endonuclease G 
EDTA        Ethylenediaminetetraacetic acid 
EGF          Epidermal Growth Factor 
E30                   Ectoin (30mM) 
ELISA        Enzyme Linked Immuno-sorbent Assay 
ERK    Extracellular signal-regulated kinase 
FACS        Flow Activated Cell Sorter 
FADD    Fas-associated death domain 
FasL    Fatty acid synthetase ligand 
14 | P a g e  
 
FBS          Fetal Bovine Serum 
FSC        Forward Scatter 
FasR    Fatty acid synthetase receptor 
 IAPs    Inhibitors of apoptosis proteins 
GAGs         Glycosaminoglycans 
IGH        Ispat General Hospital 
JNK    c-Jun N-terminal kinases 
hAdMSCs            human omentum Adipose derived MSCs 
HLA          Human leukocyte antigen 
HTS    Hypothermosol 
HtrA2/Omi   High-temperature requirement 
KV    Kilo Volts 
kDa        Kilo Dalton 
MAP kinase   Mitogen activated protein kinase 
Me2SO   Dimethyl sulfoxide 
MPT    Mitochondrial permeability transition pores 
MNCs         Mononuclear Cells 
Me2SO      Dimethyl sulfoxide or DMSO 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) 
N2           Nitrogen 
p53    Tumor protein 53 
PARP    Poly (ADP-ribose) polymerase 
PBS        Phosphate Buffered Saline 
ROS    Reactive oxygen species 
RIP    Receptor interacting protein 
RT-PCR  Reverse Transcription Polymerase Chain  
RPMI        Rosewell Park Memorial Institute 
15 | P a g e  
 
SEM         Scanning Electron Microscope 
SSC        Side Scatter 
SVF        Stromal Vascular Fraction 
SF               Silk fibroin 
SMAC/DIABLO        Second mitochondria-derived activator of Caspases/direct IAP binding 
   protein with low PI 
SD-282   Indole-5-carboxamide (ATP-competitive inhibitor of p38 kinase) 
S/N  ratio  Signal to noise ratio 
 tbid    truncated Bid 
TNF    Tumor necrosis factor 
TNF-a   Tumor necrosis factor alpha 
TNFR1   Tumor necrosis factor receptor 1 
TRADD   Tumor necrosis factor receptor type 1- associated DEATH domain  
   protein 
TRAIL   TNF-related apoptosis-inducing ligand 
T30/E30C100/I         Trehalose (30mM), Ectoin (30mM), Catalase 
     (30mM)  & apoptosis inhibitor 
T30              Trehalose (30mM) 
UC               Umbilical Cord 
UCB      Umbilical Cord Blood 
ZVAD-FMK   Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- ﬂuoromethylketone 
 
 
 
 
 
 
16 | P a g e  
 
 
GENERAL INTRODUCTION 
1.1 Background 
Millions of people worldwide have been suffering from various tissue and blood related 
diseases such as diabetes, parkinson diseases, osteoarthritis, bone, cartilage, tendon, muscle, 
neuronal etc. due to the consequence of trauma, degeneration, birth defects, infection and 
others. The current clinical treatment methods involving autograft, allograft and xenograft 
suffer from several limitations including immune-rejection, donor site morbidity and disease 
transmission [1]. As a result, none of these methods is able to fully cure the patients from such 
diseases and ultimately suffering continues. In this context, cell and tissue based therapies 
have emerged as promising techniques for the treatment of such diseases [2]. However, for 
success of this technique, a wide variety of cells and cell-scaffold constructs (cell seeded on 
artificial extra cellular matrix) are needed to be supplied to the health sector.  
Mesenchymal stromal cells or mesenchymal stem cells (MSCs) are multipotent cells present 
in all tissues and have the ability to differentiate into several cell types including osteoblast, 
adipocytes, chondrocytes, skeletal muscle cell, myoblast and the like. Recently, MSCs and 
MSCs derived tissue engineered constructs (TECs) have been considered as the most 
promising clinical products that can be used for a variety of therapeutic and tissue engineering 
applications. This has lead to many researchers worldwide to produce MSCs and MSCs 
seeded tissue engineered constructs (TECs) for their therapeutic applications in repairing and 
replacing defect and/or diseased tissues and organs.  However, the long-term storage of these 
cells and constructs   is the most critical aspect to ensure the off-the-shelf availability of such 
products for clinical applications at the time of injury or diseases. In this context, 
cryopreservation using freezing medium consisting of a suitable cryoprotective agent has been 
considered as an effective preservation method. Freezing solution containing Me2SO as 
cryoprotective agents is normally used for preservation of various cells and other biological 
species. However, freezing protocol using Me2SO as cryoprotective agent in freezing solution 
is reported to have several detrimental effects on the cryopreserved cells that are harmful to 
patients. Therefore,  an urgent research program calls for the development of an appropriate 
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cryopreservation strategy using freezing medium using a cryoprotective agent alternative to 
toxic Me2SO to meet the growing demand of MSCs and TECs for clinical applications.  
1.3 Cryopreservation of cells and tissues 
1.3.1 Principle of cryopreservation 
Cryobiology is a new modern science studies effect of low temperature on biological system. 
Cryobiology is the branch of science, which deals with the effects of reduced temperatures on 
living organisms, their constituent parts, and their products. [3] Cryobiology is the study of 
the effects of extremely low temperatures on biological systems, such as cells or organisms 
diversity of cells and other biological materials. The main aim of cryobiology is to protect and 
preserve viable cells and tissues at very low temperature for a long duration of time without 
alteration of their characteristics.   
 
1.3.2 History of cryopreservation 
In 1949, Polge and colleagues discovered the effectiveness of glycerol as a cryoprotective 
agent for fowl spermatozoa [8]. These early studies resulted in the development of the 
discipline that is now known as cryobiology. Within a few short years, human red blood cells 
were successfully cryopreserved. In the 1960s, Peter Mazur conducted extensive experiments 
to model the responses of microorganisms when subjected to low temperatures and freezing 
[6]. Through the 1960's other call lines were successfully cryopreserved along with unstable, 
complex bio-organic molecules especially labile proteins, In 1972 the methodologies 
necessary for the maintenance of "frozen" embryos were developed [7] and new concepts in-
vitro fertilization were adopted. To date, list of cell lines and tissue types that are routinely 
cryopreserved is extensive. Both profit and non-profit banking system exist worldwide. 
1.4  Important factors involved in cryopreservation 
1.4.1 Ice formation in a cell suspension  
An aqueous solution usually supercools at few degrees below its freezing point before 
freezing is initiated by heterogeneous nucleation that is by a foreign particle (nucleating 
agent) that mimics the organization of water molecules in ice and catalyzes ice crystallization. 
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Once nucleation occurred ice crystal growth starts, the amount of water that separates from 
the solution to form ice increases progressively with decreasing temperature [8].Evidence to 
suggest that although intracellular freezing is initiated by heterogeneous nucleation, 
intracellular nucleators are very inefficient [9]. Consequently, when a cell suspension is 
cooled, the cells super cool to a greater extent than the bathing medium, and freezing occurs 
almost exclusively in the extracellular solution. The resulting increase in extracellular solute 
concentration lowers the chemical potential of water outside the cells, which are, therefore, no 
longer in osmotic equilibrium be with the external solution. Under these conditions, the 
chemical potential of water inside the cells could be lowered and osmotic equilibrium is 
restored in three ways: by an efflux of water, by an influx of solute, or by intracellular 
freezing. As a consequence of the semi permeable properties of the plasma membrane, many 
types of cell respond as osmometers to changes in the extracellular concentration of 
nonpermeating solutes. Osmotic equilibrium is restored, therefore, by the movement of water, 
rather than solute, across the plasma membrane; water moves from the region of higher to the 
region of lower chemical potential until the chemical potential of water is once more the same 
on both sides of the plasma membrane. Consequently, cell volume is a linear function of the 
reciprocal of external osmolality [10].  
1.4.2 Rates of cooling and warming 
Cooling rate is one of the major factors affecting cell survival after freezing and thawing. 
Each cell type has its own characteristic optimum cooling rate, which is, to a large extent, 
determined by the water permeability of the cell but also influenced by the presence of 
cryoprotectants. The terms rapid and slow cooling for a particular cell type are defined in 
relation to the optimum cooling rate. The decline in survival at rates higher than the optimum 
is due to the likelihood that cells contain ice [11]. Although the formation of intracellular ice 
during cooling is not necessarily harmful, the consequences of the presence of intracellular ice 
during warming are usually lethal [12-18].  
Several mechanisms have been proposed for slow-cooling injury: namely, direct damage to the 
membrane caused by high electrolyte concentrations [19-20]; excessive cellular shrinkage, which 
results in damaging stresses in the plasma membrane [21-25]; thermal shock and dilution shock 
[26]; and changes in the volume of the liquid phase in the ice lattice [27].  
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Some types of cell, however, survive rapid cooling when they are cooled by the so-called two-
step method [28-35]. Cells are initially cooled to a relatively high subzero temperature (e.g., - 
25°C), held at that temperature for a few minutes, and then cooled rapidly by immersion in liquid 
nitrogen. The period spent at the intermediate temperature allows the cells time to dehydrate 
sufficiently to avoid intracellular ice formation during subsequent rapid cooling in liquid 
nitrogen. 
The survival of cryopreserved cells is also dependent on the rate of warming [36-38]. When 
cells are cooled at rates higher than the optimum, they are likely to contain intracellular ice; the 
survival of these cells is higher when warming is rapid than when it is slow. Furthermore, cells 
cooled at suboptimal rates survive better when; for example, the first successful recovery of 
mouse embryos was achieved only when they were both cooled and warmed slowly [39]. 
 
1.5  Cryoprotectants 
Cryoprotectants are chemical compounds that are able to protect cells against the stresses of 
freezing and thawing. Glycerol and Me2S0 are the most widely used cryoprotectants, but there 
is a large range of chemically diverse additives that possess cryoprotective properties [40, 41]. 
The only common features that these compounds seem to possess are high solubility in water and 
low toxicity to cells. Cryoprotectants are divided broadly on the basis of whether they permeate 
cells; for example, cells are permeable to glycerol and Me2S0 but are impermeable to sucrose 
and dextran. Although direct interactions between cryoprotectants and cells cannot be 
excluded, the main effect of additives, such as glycerol, is to reduce both the amount of ice 
formed and the rise in electrolyte concentration at any given temperature [11]. The high molecular 
weight of polymers, such as polyvinylpyrrolidone, precludes a similar colligative effect. 
However, their extremely non ideal behavior at high concentrations can reduce the amount of 
water that crystallizes [42, 43]. Cryoprotectants do not mitigate the effects of intracellular 
freezing; instead, the presence of a cryoprotectant can reduce the cooling rate at which intracellular 
nucleation first occurs [44]. Cryoprotectants are therefore only effective at protecting cells 
against slow cooling injury, and as the initial concentration of cryoprotectant is increased, the 
optimum cooling rate is reduced and survival improves [45]. In two-step cooling procedures the 
main action of a cryoprotectant is thought to permit survival of the cells at the intermediate 
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holding temperature, rather than during subsequent rapid cooling. The optimum holding 
temperature is itself dependent on cryoprotectant concentration [46, 47]. Cryoprotectants are 
divided into two types: membrane-permeating (e.g., glycerol, ethylene glycol (EG), dimethyl 
sulfoxide (Me2S0), propanediol) and membrane non-permeating (e.g., sucrose, glucose, Ficol, 
proteins, lipoproteins).  
1.5.3 Cryoprotectant and toxicity  
Cryoprotectants are reported to have adverse effects on cells due to chemical toxicity, or they 
could be a result of osmotic stress during the addition of the cryoprotectant before freezing and 
during dilution of the cryoprotectant after thawing. If a cell is more permeable to water than to a 
solute, then a sharp increase in the concentration of that solute in the bathing medium  results in 
cellular shrinkage as water moves out of the cell to restore osmotic equilibrium.. It is accompanied 
by water, and the cell returns asymptotically to its normal volume. Conversely, if the external 
concentration of the solute is reduced abruptly, the cell will swell as water enters to restore 
osmotic equilibrium. The cell then returns to its normal volume as solute and water leave the cell 
simultaneously. Reducing the rate of change of solute concentration reduces the associated 
osmotic stress. Stepwise addition and dilution protocols to minimize osmotic stress can 
be devised in a rational manner, instead of empirically, providing that values for certain 
parameters are available for the cell: namely, the limits to which the cell can shrink and 
swell without damage and the membrane permeability coefficients.  
1.6 Stem cells  
Stem cells are exceptional cells with unique ability to differentiate into diverse cell types in 
the body, right from the time of nativity to death of an organism [3]. They are found in 
internal repair systems where they divide without limit, to either repair or replace damaged 
and diseased cells throughout a person’s life. A stem cell has the capability of forming a new 
cell that either has the potential of a stem cell or becomes a more dedicated type of cell with 
definite function. Stem cells can be defined as undifferentiated cells with high proliferative 
capacity, self renewal ability and are found in all multi-cellular organisms. Stem cells are 
distinguished from other cell types by two important characteristics: i) they are 
undifferentiated cells, capable of self-renewing for continued periods of time. ii) They can be 
21 | P a g e  
 
differentiated into a more dedicated lineage with specialized functions under certain specific 
physiological environmental conditions.  
1.6.1 Types of stem cells  
Stem cells are of three types based on their proliferation potential namely totipotent stem 
cells, pluripotent and multipotent stem cells. totipotent stem cells are obtained after initial cell 
division from a fertilized ovum and have the capacity to become all cell types including 
placenta. After blastocyst stage, cells become pluripotent, which develop into cells from the 3 
primary germ layers. Multipotent cells can develop into cells that are closely related to where 
they reside and self renew for a lifetime. Some sources of stem cells have a potential to 
differentiate to lineages of endoderm, ectoderm and mesoderm which form the entire human 
body whereas others are more specialized to differentiate into a few lineages only. There are 
two types of stem cells namely embryonic stem cells and somatic or adult stem cells. 
Embryonic stem cells (ESCs) are derived from the inner cell mass of 3 to 5 day old embryo. 
ESCs can give rise to the entire body of the organism, including all of the many specialized 
cell types and organs.  An adult stem cell is an undifferentiated cell, found among 
differentiated cells in a tissue or organ [5]. The primary role of adult stem cells in a living 
organism is to maintain and repair the tissue in which it is found [3-7]. However, in recent 
past experiments have shown that they can differentiate to cells that are not closely related to 
them by the phenomenon called transdifferentiation [5, 8]. Adult stem cells are 
immunocompatible, immunomodulators and immunosuppressant, and there are no ethical 
concerns with their use. 
1.6.3 Mesenchymal stem cells  
The most promising attractive stem cell sources for the regeneration or repair of damaged 
tissues. MSCs have the ability to proliferate in vitro and differentiate into a series of 
mesoderm-type lineages, including osteoblasts, chondrocytes, adipocytes, myocytes, vascular 
cells and the like [9-14]. The advantages of MSCs as potential source for tissue engineering 
are: ease of availability and large quantity of starting samples for isolating cells [12], high 
proliferation ability, no sign of senescence for >16 passages [10], immuno-compatible and 
immunosuppressant, useful in autologous and allologous stem cell transplantation, no 
formation of teratomas or tumor as in case of ESCs [15-16], immuno-modulator property, 
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useful in GHVD and inflammation [17-18], no ethical concerns. MSCs were first identified by 
Friedenstein and Petrakova (1968) [19] from rat marrow as plastic adherent bone-forming 
progenitor cells. MSCs in culture have a fibroblastic morphology and adhere to the tissue 
culture substrate [20]. MSCs isolated from bone marrow are obtained by invasive procedure 
and it has been found that the passaging capacity, maximum culture lifetime as well as 
differention potential [21-24]. The  potential sources are bone marrow, umbilical cord (UC), 
umbilical cord blood (CB), placental tissue (PT), adipose tissue (AT) , amniotic fluid (AF) 
and the like. The MSCs s derived from all these sources may but differ in proliferation and 
differentiation capability [25-26].  
However the advantage of using birth associated tissues like UC, CB, AF and PT are ease of 
their availability in large quantity, non invasive procedure to harvest, usually discarded as 
waste and ability to proliferate and maintain self renewal capacity for longer period of time in 
culture, unlike BM-MSCs [6]. AT is also less invasive source available in large quantity and 
AT derived stromal cells (ASC) has shown similar properties as bone marrow derived 
mesenchymal stem cells (BM-MSCs) [12, 27]. Phenotypically, the minimal criteria to 
consider human MSCs are adherence to plastic surface, >95% expression of CD105, CD73, 
CD90; < 2% of CD45, CD34, CD14 or CD11b, CD79α or CD19, HLA-DR and 
differentiation to osteoblasts, adipocytes, chondrocytes [28]. 
1.7 Cryopreservation of Tissue Engineering Construct 
Tissue defects are one of the most frequent, devastating, and costly problems in human health 
care. The need for substitutes to repair restores, or replaces tissues due to disease, trauma, or 
congenital problems is over whelming. In recent years, tissue-engineering constructs (TECs) 
that can be developed by seeding of cells on the scaffold (artificial ECM) through tissue 
engineering technique. TECs have the potentiality to revolutionize current methods of health 
care treatment and significantly improve the quality of life of patients when compared with 
the three major types of clinical treatment methods are currently utilized: autograft, allograft 
and xenograft. However, living TECs are not easily available due to time and space 
constraints. One of the major obstacles in the industrialization and large- scale clinical 
applications of tissue engineering is the preservation of TECs. TECs stored at ambient 
temperature require expensive human involvement to satisfy metabolic demands and can be 
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potentially infected and biologically altered. Safe and long-term preservation methods for 
these engineered tissues are needed [29-31].    
Organisation of thesis 
The work embodied in this thesis has been presented in the following six chapters  
Chapter I: Presents a general introduction emphasizing on the background of the study, 
preservation techniques for cells and tissue, principle of cryopreservation, history of 
cryopreservation and important factors involved in cryopreservation. The problem associated 
with cryopreservation of stem cells and cryopreserved TECs have been highlighted.  
Chapter II: An extensive literature survey on the preservation of MSCs, cryoprotectants 
alternative to DMSO for preserving MSCs, cryopreservation of TECs and cryopreserved 
induced cell death has been presented. 
Chapter III:  Includes the aims and scope of the present work. 
Chapter IV: Describes the materials and detailed experimental procedure to carry out various 
stages of present research work including i) collection and isolation of MNCs ii) sorting and 
culturing of MSCs iii) Characterizations before and after cryopreservation of MSCs iv) 
Cryopreservation study on MNCs and MSCs iv) Cryopreservation study of MSCs seeded 
TECs vi) Characterizations of TECs before and after cryopreservation.   
Chapter V: Deals with the results and discussion on the experimental work. The results and 
discussions section is divided into three phases. The first phase includes the cryopreservation 
of MNCs for the selection of most efficient natural CPAs included in this phase. The second 
phase involves the Cryopreservation of MSCs using most efficient CPA with the aim to 
improve long term cryopreservation efficacy MSCs.  In the last phase of this chapter 
Cryopreservation of TECs using most efficient freezing solution has been presented. 
Chapter VI:  Includes a brief summary and conclusion of the whole investigation.
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LITERATURE REVIEW 
 
2.1  Preservation of MSCs  
Cryopreservation plays a vital role in obtaining off the-shelf availability for a variety of tissues 
and cells[4]. Recently MSCs are considered to be the main cell source for tissue engineering and 
stem cell therapy. The availability of stem cell and amount makes cryopreservation important 
[32].  If stem cells can be cryopreserved for long duration with retention of high level of viability 
and potentiality to differentiate into tissue-speciﬁc cells, their clinical applications are greatly 
simpliﬁed. However, an important prerequisite for prospering applications of MSCs is to 
cryopreserved these cells under well deﬁned conditions to satisfy needs in clinical applications. 
Currently, there are available approaches for cryopreservation of cells such as (i) typical slow 
cooling and (ii) vitriﬁcation using Me2SO as CPA. 
Slow freezing has the advantage of using low concentrations of CPAs, which are reported to be 
associated with chemical toxicity and osmotic shock [33-34].  More significantly slow freezing 
can handle large quantity of cells, which makes it more clinically relevant. After the invention of 
glycerol as cryopreservation of sperm in 1949 [5], it has become a common practice to add one or 
several CPAs to the freezing media [6]. Afterwards, the discovery of Me2SO as cryoprotectant 
increases the growth of cryopreservation applications. Recent studies have confirmed that 10% 
Me2SO and slow cooling/rapid warming does not affect the viability or differentiation potential of 
adipose-derived MSCs [7]. Adult MSCs derived from human dental pulp also showed high post-
thaw recovery and trilineage differentiation potential after slow cooling in 1–1.5mol/l Me2SO [8]. 
Me2SO is known to have an effect on the epigenetic profile of, and induce differentiation in, 
murine stem cells [9]. Cryopreserved cells treated with Me2SO may cause other adverse effect 
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including gene mutation. Therefore, it is important to reduce the levels of Me2SO in freezing 
solutions even if complete elimination is not possible.  
2.1.1 Alternative cryoprotective agents for preserving MSCs 
The use of polyvinylpyrrolidone (PVP), an extracellular cryoprotectant, has been investigated as 
an alternative to Me2SO and fetal calf serum (FCS) [14-13] for cryopreservation of  MSCs. 
Recovery of MSCs cryopreserved in 10% PVP with human serum was slightly lower than cells 
cryopreserved in Me2SO with animal serum as reported[10]. A similar study utilizing 
methylcellulose either individually or in conjunction with reduced levels of Me2SO indicated that 
human serum could replace in standard Me2SO mixtures without affecting the recovery of cells 
[11] and that 1% methylcellulose produced comparable results with Me2SO concentrations as low 
as 2% when an annexin V apoptosis assay was used to analyze cells after 24 h post-thaw [12]. In 
an another study, MSCs exposed to trehalose loading medium for 24 h prior to addition of 
cryoprotectant mixture (10% Me2SO and serum)[13] showed significant increase in post-thaw 
viability of more than  50% . They showed a beneficial effect of trehalose in the elution solution, 
Polyampholytes (polyelectrolytes bearing both cationic and anionic repeat group) such as poly-L-
lysine have been used successfully to cryopreserve MSCs isolated from rat [14] and may offer an 
alternative to Me2SO. Sericin (a protein derived from the silkworm) has been shown to improve 
the attachment of cryopreserved hepatocytes and mammalian cells [15-17]. 
2.1.2  Use of antioxidants and inhibitors as additive in freezing medium 
Antioxidants in the form of β-mercaptoethanol are routinely present in culture medium of human 
embryonic stem cells (hESCs). But the overproduction of reactive oxygen species (ROS) during 
cryopreservation has led to the addition of antioxidants to the freezing solution in an attempt to 
reduce damage [35- 36]. Addition of glutathione to the cryoprotectant and post-thaw recovery 
solution has shown an improvement in the survival of embryonic stem cells following 
cryopreservation [18-20]. Rho-associated protein kinase (ROCK) inhibitors have been reported to 
improve post-thaw survival in a number of studies [38-42]. It has been demonstrated that Y-
27632 added to the post-thaw culture medium increased hES survival rate 10-fold, with colony 
growth rates similar to unfrozen controls [21]. Furthermore, the effect of ROCK inhibitor Y-
27632 has shown to have similar effects on the recovery from cryopreservation of both adult stem 
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cells and bone marrow-derived MSCs[22] as well as human iPS cells in both feeder-associated 
and feeder-free conditions [43]. 
 
It is reported that Rho GTPase enzyme target rho-associated kinase I (ROCK-I) is cleaved by 
caspase inhibitor during apoptosis and activated ROCK-I brings about bleb formation in apoptotic 
cells [27] which is one of the essential characteristics of apoptosis. A potent ROCK matter Y-
27632 inhibits apoptosis and is proved to be effective in increasing post thaw recovery and 
survival of many cryopreserved cells like human embryonic cells , induced pluripotent stem cells 
(iPS cells), human mesenchymal cells, cord blood-derived CD34+ hematopoietic the cells and 
frozen human embryos. Targeting and inhibiting Furthermore, various molecules including 
proteases, signaling molecules and other proteins bring about apoptosis and necrosis down the 
cell death cascades is the prime goal of the researchers in this field.  
Various caspase inhibitors are reported to provide protection against apoptosis [44].  The most 
widely studied is the synthetic broad-spectrum irreversible inhibitor of caspase enzymes and N-
Benzyloxycarbonyl-Val-Ala-Asp (O-Me) fluoromethyl ketone (zVAD-fmk) [45]. However, 
incorporation of only zVAD-fmk in the freezing medium, does not much improve post thaw cell 
viability. But an increase in cell viability is observed when it is added to post thaw culture 
medium and incorporated in both freezing and post thaw culture medium [38]. In another study, 
zVAD-fmk not only inhibited caspase activity in cryopreserved cells but also reduced 
mitochondrial injury by caspase inhibition by increasing mitochondrial membrane potential in 
cryopreserved porcine hepatocytes [39]. As mentioned earlier, cryopreservation induced stress 
activates mitochondrial death pathway resulting in an increase in mitochondrial membrane 
permeability and reduction in mitochondrial membrane potential. Besides zVAD-fmk, there are 
many other potential caspase inhibitors has been reported. Recently Xia Xu et. Al.1999 studied 
caspase-9 inhibitor and zVAD-fmk [46]. They reported that though these inhibitors significantly 
inhibited caspase-8 and caspase-9 activity, but they did not enhance post thaw cell viability [23]. 
This implies that inhibition of caspase activity does not protect the cells [24]. Hence it is stated 
that caspase 8 and caspase 9 acts as downstream effectors in cryopreservation induced cell death 
and their inhibition does not improve cell recovery.  
Ferrusola et. al. (2010), reported that the addition of bongkrekic acid (BA), a specific inhibitor of 
mitochondrial permeability transition pore (PT–pore), during cryopreservation of sperm stallion, 
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significantly reduced caspase activity after thawing, reduced the increase in membrane 
permeability, and increased the mitochondrial membrane potential of thawed sperm cells [47]. 
The addition of broad spectrum protease inhibitors to the cryopreservation medium significantly 
reduces the cleavage of apoptosis proteins like caspase 3 and 8 as reported [48]. The p38 MAPK 
is one of the mitogen-activated protein kinase (MAPK) signal transduction pathways which can 
be activated in response to various environmental stimuli and induce apoptosis. It is shown to be 
activated during freezing-thawing and cryopreservation processes [49-51]. Inclusion of p38 
MAPK inhibitor (SD-282) inhibits the phosphorylation of p38 MAPK substrate, heat shock 
protein (HSP27), which in turn reduces cell damage/apoptosis, thereby results in the improvement 
in viability of cryopreserved cells [52].   
The F-actin cytoskeleton plays a vital role in various cellular functions like cell motility, shape 
and regulating complex signaling systems [53]. It has been observed that alteration of the 
equilibrium between G-actin and F-actin in response to environmental stimuli can induce 
apoptosis in mammalian cells [54]. Cytoskeleton may be affected by hypertonic conditions and 
may bring about remodeling of actin [55]. It is well known fact that during cryopreservation, cells 
are exposed to anisotonic conditions, which result in elevation of F-actin levels inside cellular 
cytoplasm [56]. This elevation in F-actin levels itself may be the reason for low recovery after 
cryopreservation as alteration in cellular F-actin levels causes apoptosis [57]. Rho GTPases is 
reported to regulate cytoskeleton dynamics.  In particular, ROCK triggers a signalling pathway 
that leads to actin-myosin coupling to the plasma membrane leading to the contraction of actin-
myosin and blebbing of plasma membrane [58-62]. It has been reported that ROCK pathway can 
be activated by a variety of external stimuli including osmotic stress [63]. Pizzolla D. et al. has 
reported that ROCK leads to phosphorylation of ezrin, resulting in clustering of FAS and 
ultimately apoptosis via extrinsic pathway [64]. A potent ROCK inhibitor Y-27632 inhibits 
apoptosis and is proved to be effective in improving the post thaw recovery and survival of many 
cryopreserved cells like human embryonic cells hESCs), induced pluripotent stem cells (iPS 
cells), human mesenchymal cells and frozen human embryos[65-75] except for cord blood-
derived CD34+ hematopoietic progenitor cells [76]. It has been reported that the inhibition of 
ROCK by Y-27632 following cryopreservation reduces caspase 8 activity [64]. Thus ROCK is 
involved in the regulation of activation of caspase 8 during cryopreservation which may be 
through ezrin phosphorylation and induces apoptosis via extrinsic pathway. However, it is still not 
29 | P a g e  
 
clear whether caspase 8 induces apoptosis directly or via mitochondrial pathway. Thus the 
mechanism of cryopreservation induced ROCK pathway and relation between F-actin and ROCK 
needs to be further studied. Recently, Barbaric et. al. found an  alternative to the potent ROCK 
inhibitor Y-27632. They found an FDA approved drug, pinacidil through a high-throughput 
screening assay with similar properties to that of Y-27632. Like Y-27632, the compound is 
reported to promote attachment of post thawed hESCs, reduce apoptosis and enhance their 
survival when added to the post thaw culture medium [76]. The advantage of pinacidil over Y-
27632 is that it has been used over many years as a vasodilator drug for treating hypertension, its 
availability and much cheaper than Y-27632, thus, it is expected to develop cryopreservation and 
post thaw culture medium economical. 
As mentioned earlier, in response to various stimuli, p53 plays an important role in regulation of 
apoptosis [52]. At low levels of reactive oxygen species (ROS), p53 acts as a survival factor but at 
higher concentrations, p53 induces the expression of pro-oxidant genes [76]. Xu et al. have 
reported that Bax-peptide inhibitor promotes cell recovery to some extent and also demonstrated 
and correlated the high level of intracellular ROS and p53 activation caused by the procedure of 
freezing in cryopreservation. They have also reported that in presence of p53 inhibitor, pifithrin µ, 
there was a reduction in caspase 9 activity but not caspase 8 activity [77]. This suggests that 
apoptosis following cryopreservation may be induced by activation and accumulation of p53 in 
the cytosol through the intrinsic pathway. Furthermore, study has shown that there is an increased 
level of LC3-II (phagophore protein to lysosomal degradation) during storage of stallion 
spermatozoa [78]. Autophagy is reported to be detected after cold storage of fatty livers [79]. 
However, further study is essential to understand the exact relationship between autophagy and 
cell survival due to cryopreservation.  
2.2 Cryopreservation of TECs  
Biopreservation techniques that maintain ex-vivo TECs viability and function represents the 
foundation of modern tissue engineering. The ability to preserve the integrity of TECs outside the 
native environment for extended periods has not only separated donors and recipient’s time, but 
also has made it possible for bio-banks to provide safe, high quality TECs products in an efficient 
and effective manner.  It is fact that successful cryopreservation of ready to use TECs would 
support the implementation of routine cryopreservation practices during preparation of engineered 
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cells and tissues for clinical applications and beneﬁt high throughput cell based assays by 
reducing batch to batch variation and eliminating the time consuming, labor intensive process of 
inoculation and expansion from a frozen vial of cells, thus reducing time between cell storage and 
use in experimental settings. For this reason, cryopreservation of not only cells, but also tissue 
engineered constructs (TECs) is an important part.   
 
Various natural and synthetic materials have been used to construct extracellular matrices (ECMs) 
for in vitro cell culture and in vivo tissue regeneration. The biomaterials used as scaffolds are 
natural or synthetic polymers such as polysaccharides, hydrogels or thermoplastic elastomers. 
However, there is currently no scaffolding material that simultaneously offers superior 
biocompatibility, biofunctionality, effective mechanical properties and tractability.  
There are several challenges of cryopreservation of TECs such as preservation of integrity of 
TECs (Table 1) adapted from Sarangi et al [25]. Maintenance of cell-cell interaction, cell 
substrate contact, cell viability, cell functions, cell proliferation and differentiation ability, It was 
hence the objective of this review to discuss how the surface properties of biomaterial affect 
cryopreservation outcome of adherent hMSCs.   
Table1: Factors influencing cryopreservation of TEC 
Irregular physical dimensions of TECs Uneven distributions of cryoprotectant occur, 
some regions are not sufficiently protected due to 
low concentration of cryoprotectant and some are 
damaged by over exposure to the cryoprotectant. 
Non uniform rates of temperature change Optimal cooling and warming rates are difficult to 
achieve in large sections of the tissue constructs.   
Thermal gradients difference Uneven expansion or contraction in the TECs 
Vascularization of tissue Vascularisation results in extracellular ice 
formation inside the  intravascular space, 
ultimately resulting in over distention and  rupture 
of blood vessels and sinusoids  
 
Stem cell transplantation has been in clinical use for decades to treat diseases. The principal 
sources for those therapeutic strategies are stem cells derived from umbilical cord blood, non 
hematopoietic stem cells, such as embryonic and induced pluripotent stem cells. The therapeutic 
strategies utilizing such cellular products depend heavily on the effective preservation of those 
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cell products for clinical use. The need for ready availability of such products calls for appropriate 
storage procedures with favorable graft survival rates and a tolerable toxicity profile. Broad 
research on stem cells open an area of promising therapeutic ability of stem cells has shed light on 
shortage of tissue grafts. Stem cells derived from bone marrow, cord blood, cord, adipose tissue, 
dental pulp are considered as an important source for tissue regeneration. These stem cells have 
shown good proliferation and differentiation ability into various functional cell types of 
mesenchymal tissues, including bone, cartilage, tendon, fat and have been considered appropriate 
candidates for various tissue regeneration. MSCs derived from various source can be successfully 
cryopreserved in suspension, such as embryonic stem cells, with high recovery of viability and 
functions, but this technology has not been successfully extended to cells on substrates/scaffolds. 
Only limited success has been achieved in cryopreservation of encapsulated hepatocytes. The 
majority of cell scaffold construct have been shown not to accommodate freezing protocols due to 
various factors such as various location in the tissue changes the concentration of cryoprotectant 
and temperature which leads to non uniform mass and heat transfer [26-27]. 
2.2.1 Cryopreservation of TECs by slow freezing 
Polge et al. in 1949 was first reported the successful slow cooling protocol using glycerol as 
cryoprotectant[28]. Slow cooling consists of steps of various steps like CPA addition, seeding, 
cooling, thawing and CPA removal. The traditional methods used for cryopreservation of TECs 
are based on the slow cooling approach. For this, TECs are usually cooled in presence of one or 
more cryoprotectant, at a selected cooling rate in a programmable freezing device. The slow 
cooling rate allows TECs to partial dehydration by maintaining equilibrium with the frozen extra-
cellular environment. For successful cryopreservation, cooling rate is most important part as it 
determines the rate of water efflux from cell to extracellular component. However, slow freezing 
method is not cost-effective as it requires a controlled rate freezer. More significantly, it is 
extremely tricky to preserve the intactness of biomaterials and the integrity of neo-tissue during 
the liquid-ice phase transition[4, 29]. Uncontrolled freezing i.e. at -20ºc and -80ºc is reported to 
more injurious for fragile TECs seeded with stem cells. Table 2 shows the some of the important 
cryopreservation study on tissue engineering constructs. 
2.2.2 Cryopreservation of TECs by vitrification 
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Vitrification refers to the physical phenomenon relating the solidification of any solutions into a 
glass state. Vitrification occurs due to rise in viscosity during sudden cooling which eliminate ice 
formation. Vitrification of cells depends on various factors such as (a) cooling and warming rates 
(b) concentration of cryoprotectant (c) substitution of an amino group for the hydroxyl (OH
−
) 
group of an alcohol (d) hydrostatic pressure of the solution (e) reduction of Cv (f) sample size and 
carrier systems [80]. Table 2 shows some of the important cryopreservation study on tissue 
engineering constructs.  
 
 
Table 2: Cryopreservation of tissue engineering constructs by vitrification as reported 
Year Author Cryoprotectant Application Morphology/viability 
2004 Pegg, D Me2S0 Cartilage Inadequate  and variable  
2006 Han, D 10%Me2SO & 20% FBS Osteoblasts  50% 
2006 Wang 10% Me2SO  PGA seeded dermal 
cells 
Regain its natural shape &  No 
fracture was observed 
2013 Chen 10% Me2SO Alginate encapsulation 
stem cells 
Gave 74% (mESC) and 
80%(hMSC) survival rates 
2010 Malpique CryoStor Neurospheres 60% 
2009 Malpique CryoStor & 10% Me2SO N2a, Caco-2 91 ± 15% and 68 ± 15% 
2011 Khalil  12% Me2SO/Celsior+/-  Liver Spheroids Improve multi-cellular constructs 
2009 Miyoshi 10% Me2SO Bioartiﬁcial livers 65% cell attached to scaffold 
2006 Lehle 10% Me2SO Vascular tissue Between 60% and 80% 
2009 Sui 10% Me2SO  3Dgelatin constructs  78.7 ± 3.94% 
2011  Sambu 20 % (v/v) Me2SO ESCs alginate beads 60 % 
2013 Massie 15% Me2SO HepG2 monolayer 
cell  & Alginate 
encapsulation  
65% to  80%  
2011 Umemura 10% ethylene glycol 
1.0M sucrose & 0.00075 
M (PVP) 
3D gelatin 49% to 96% 
2012 Costa Me2SO Starch & PCL blend   Off-The-Shelf Engineered 
Tissue Substitutes 
2012 Xu 10% Me2SO glass,gelatin, matrigel 
and a matrigel 
sandwich 
cell viability of adherent hMSCs 
is signiﬁcantly lower (up to 
35%) 
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2011 Chen Me2SO & trehalose  Epithelial sheets  Mechanical property decreased  
 
2.3 Cryopreservation induced cell death 
Cryopreservation is defined as the promising technique of storing biological living cells and 
tissues at sub freezing temperatures below -80°C and particularly at a cryogenic temperature 
below -140°C. In long term storage of cells, tissues and other biological materials,  during 
cryopreservation, cells face various physical and chemical stresses such as cold stress, formation 
of intracellular and extracellular ice crystals, osmotic stress during cryoprotectant addition and 
removal, solution effects and chemical toxicity of solutes added as potential cryoprotectants [30]. 
Despite all the marked developments in cryopreservation protocols, post thaw cell death is still 
significant, especially within the first 24 h of post thaw culturing. However, the majority of 
cryoinjuries occur during the freezing and thawing processes [81]. 
During the development of preservation protocol and preservation medium, scientists have always 
focused on overcoming cryopreservation induced cell death that mainly occurs due to intracellular 
ice formation and chemo-osmotic stress leading to morphological and functional damage of cells 
and subsequent necrosis. To overcome this difficulty, many investigators have used 
cryoprotective agents like Me2SO and glycerol to preserve biologics in an extracellular-like 
carrier solution i.e. standard cell culture medium [1-5]. However, low survival rate of 
cryopreserved cells is still observed in spite of using most effective cryoprotectants like 10% 
Me2SO [6]. The involvement of molecular-based mode of cell death following cell preservation is 
first reported by Nagle et. al. (1990) under non freezing condition. This was further studied by 
Baust et. al. (2009) under freezing condition [82-85]. Later on many scientists have reported 
cryopreservation induced cell death and given efforts to modify cryopreservation solution 
accordingly. Baust et al. (2000) used Hypothermosol® (HTS) as an intracellular-like hypothermic 
maintenance solution and modified it by adding 5% Me2SO and caspase I inhibitor V to HTS to 
control cryopreservation induced cell death and traumatic necrosis [85]. The modified HTS is 
known as CryoStor® CS 5N. In their study, the addition of a caspase inhibitor showed a 
remarkable improvement in cryopreservation outcome as compared to the parent solution without 
adding inhibitor.  
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2.3.1 Modes of cell death 
Multicellular organisms eliminate unwanted, damaged or dying cells by two main mechanisms: 
necrosis and apoptosis. Necrosis or pathological cell death is an energy independent process that 
is characterized by cellular and organelle swelling, formation of blebs and vacuoles, 
disaggregation and detachment of ribosomes, loss of organelle and cell membrane integrity and 
rupture, random DNA degradation by endonucleases resulting in cell lysis and activation  of 
active immune and inflammatory response due to release of cytokines [86-92]. Necrosis is 
triggered by multiple stresses such as osmotic shock, hypothermia and cryopreservation, 
ischemia, ionic disregulation and exposure to toxic agents. On the other hand, apoptosis or 
programmed cell death is an energy dependent process involved in homeostatic maintenance of 
cell number and tissue size in complex organisms. It is characterized by the activation of 
intracellular proteases from their inactive zymogens (procaspases to caspases), cellular shrinking, 
chromatin condensation, non random cleavage of DNA into 180 KDa fragments by exonucleases, 
maintenance of intact cell membrane, externalization of phosphotidylserine, and formation of 
membrane blebs (apoptotic bodies). There is no recruitment of immune and inflammatory 
response. Apoptosis may be initiated by various stresses such as anoxia, nutrient depletion, 
withdrawal of essential growth factor, radiation, cytotoxic agents and exposure to extreme 
temperature [92-100]. 
It is believed in many cases that when a cell commits to cell death, first apoptosis is activated and 
then continues via the classical apoptotic pathway till stresses experienced by the cell exceed 
normal limits or the energy reserves become very low for apoptosis to continue. It is at this point 
the cells switch from apoptotic to necrotic pathway of cell death called secondary necrosis [101, 
102]. 
2.3.2  Apoptosis 
Apoptosis may be defined as a physiological cell death that occur in response to environmental 
and developmental signals during which dying cells silently vanish out, without any traces being 
left behind. In mammals, apoptosis can be triggered by mainly two different pathways (Figure 1) 
extrinsic pathway (Death receptor pathway) and intrinsic pathway (Mitochondrial pathway). 
There is an additional pathway termed as the granzyme pathway that involves T cell mediated 
cytotoxicity and perforin granzyme dependent killing of cell via either granzyme A or granzyme 
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B. The extrinsic, intrinsic and granzyme B pathways finally converge to a common execution 
path of apoptosis that involves proteolytic activation of caspases -3 and /or -7 from their inactive 
procaspases [103-109]. The granzyme-A pathway is a caspase independent cell death pathway 
that is characterized by single stranded DNA damage [110].  
Caspases play a major role in the final stage of “execution” in apoptosis. These are highly 
conserved family of cysteine proteases with specificity for aspartic acid in their substrates. The 
cleaveage of these substrates induces the cell death. Caspases are constitutively present in the 
cytoplasm of most of the cells in the form of single chain proenzyme (Procaspase). These proteins 
undergo two proteolytic cleavages, wherein first divides the chain into large and small domains 
and second one cleaves the N-terminal domain (prodomain) to give its fully activated and 
functional caspase.  Caspases have been broadly categorized into initiators (caspase-2,-8,-9,-10), 
effectors or executioners (caspase-3,-6,-7) and inflammatory caspases (caspase-1,-4,-5) [29, 30]. 
Caspase cascade activation and DNA fragmentation are reported to the main features of apoptosis 
[30]. Apoptotic cells also exhibit phosphatidyl serine externalisation [110]. 
2.3.3 Extrinsic and intrinsic pathway 
The receptors for extrinsic pathways located in the plasma membrane are activated by ligands 
present in extracellular membrane. Some of the well characterized ligands and corresponding 
death receptors include FasL/FasR, TNF-α/TNFR1, Apo3L/DR3, Apo2L/DR4 and Apo2L/DR5 
[111]. These receptors contain a death domain on their cytosolic side. The binding of FasL to 
FasR results in the recruitment of adaptor protein FADD (Fas-Associated protein with Death 
Domain). The attachment of TNF ligand to TNF receptor results in the binding of TRADD (tumor 
necrosis factor receptor type 1-associated DEATH domain protein) and recruitment of FADD and 
RIP (receptor interacting protein)[39, 40]. FADD then binds to procaspae-8 via dimerization of 
their death domain (DD) to the DD on the cytoplasmic side of the receptors [111] resulting in the 
formation of death inducing signalling complex (DISC) [112-117]. Formation of DISC results in 
the autocatalytic activation of initiator procaspases [31] which activates downstream effector 
caspases (caspases-3 or -7) that further carry out the degradation of cellular targets. On the other 
hand, activated caspase 8 can also cleave BH3 only protein Bid resulting in the formation of 
truncated Bid (tBid). tBid then translocates to the mitochondria, changes the permeability of inner 
mitochondrial membrane and induces release of cytochrome C, leading  to the activation of 
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caspase 9 and caspase 3 [118]. Extrinsic pathway can be blocked by the expression of c-FLIP 
(cellular form of FLICE-inhibitory protein), which is physiologically present as a negative 
caspase-8 that leads to the formation of a signalling non-functional DISC [119-124].  
The intrinsic or mitochondrial pathway is triggered by a variety of extracellular and intracellular 
stresses such as high temperature, oxidative stress (excess of reactive oxygen species), irradiation 
etc. All these stimuli result in opening of the mitochondrial permeability transition pore (MPT). 
This results in loss of mitochondrial membrane potential that leads to the release of two 
specialised types of proteins from the intermembrane space into the cytosol [124]. The first group 
of proteins consists of cytochrome c, serine protease HtrA2/Omi and Smac/DIABLO [125-128]. 
These proteins further transduce the apoptotic signal via the caspase-dependent pathway. 
Following release into cytosol, cytochrome c binds to Apaf-1 in conjunction with dATP, leading 
to the recruitment of pro-caspase-9 to this complex, termed as apoptosome [129-132] which 
contains several units of above molecules. Active caspase-9 further activates caspase-3 and 
initiates proteolytic cascade causing cell death [56]. Smac/DIABLO and Omi/HtrA2 activate 
caspases by neutralising the inhibitory effects of inhibitors of apoptosis proteins (IAPs) [133,134]. 
The second group of proteins released from the intermembrane space of mitochondria include 
AIF (apoptosis inducing factor) [135], endonuclease G [136] and CAD (caspase-activated 
deoxyribonuclease) [137]. These proteins are released generally at later stages of apoptosis. 
Apoptosis-inducing factor (AIF) and endonuclease G bring about DNA damage and condensation 
[61-63] in a caspase independent manner. CAD also results in DNA fragmentation and brings 
about a more advanced level of condensation [139]. Apoptosis also may occur due to p53 protein 
by its signalling pathway. It has been reported that signals from external stress can cause DNA 
damage, which can activate p53 protein. High level of p53 switches on the apoptosis genes and 
switches off the survival genes. The intrinsic apoptotic pathway is regulated by many p53 
regulated genes. These genes contribute to the activation of caspase 9 and ultimately cause 
apoptosis [117]. p53 protein is normally present in the cytosol at low concentration that prevents 
it from entering into the nucleus. Various cellular stress activate p53, leading to apoptosis in 
either transcription dependent manner or transcription independent manner [140]. In transcription 
independent manner, p53 directly acts on mitochondria and induces apoptosis [141-144].  p53 
also enters the nuclei and activates various pro-apoptotic genes in response to generation of 
Reactive oxygen species (ROS). 
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Figure 1: Graphical representation of two distinctive apoptosis pathways namely death receptor 
pathway (extrinsic pathway) and mitochondrial pathway (intrinsic pathway). In the extrinsic pathway 
death receptors present on cell membrane ligate due to the binding of their ligands, resulting in the 
recruitment of adaptor protein Fas-associated protein with death domain (FADD) and procaspase 8. 
The complex is an “apoptosome” in which the aggregated procaspase transactivates. The active 
caspase 8 then acts to cleave and activate the downstream caspases. Caspase 8 also activates Bid which 
further represents the main link between extrinsic and intrinsic pathways. Truncated Bid (tBid) 
favours aggregation and permeabilization of Bax and Bak to the outer membrane of mitochondria. In 
the intrinsic pathway, various forms of cellular stress cause mitochondrial membrane 
permeabilisation which triggers mitochondrial release of cytochrome c, which binds to Apaf1, which 
in turn self-associates and binds procaspase-9, resulting in an apoptosome. Transactivation of the 
complex procaspase-9 to active caspase-9 cleaves and activates downstream caspases. Mitochondria 
also initiates apoptosis in a caspase independent manner by releasing pro-apoptotic proteins like 
Smac/Diablo, Omi/HtrA2 (caspase dependent), AIF and Endo G.  
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Mitochondrial pathway is basically regulated by two types of proteins namely pro-apoptotic and 
anti-apoptotic proteins belonging to the Bcl (B-cell lymphoma 2) family of proteins [144] which 
are controlled and regulated by the tumor suppressor protein p53 [145]. The pro-apoptotic 
proteins like Bcl-10, Bax, Bak, Bid, Bad, Bim and Bik insert into the mitochondrial membrane, 
resulting in release of cytochrome c from the intermembranal space of mitochondria into the 
cytosol [146]. In contrast, anti-apoptotic Bcl-2 family members, such as Bcl-2, Bcl-x, Bcl-XL, 
Bcl-XS, Bcl-w and BAG, prevent cytochrome release by binding and inhibiting pro-apoptotic 
proteins. 
2.3.4 Necrosis and autophagy 
Necrosis also known as pathological cell death is a term used to define “cellular murder” [65]. 
Morphologically, apoptosis and necrosis are very different. However, with the development of the 
techniques which differentiate apoptosis and necrosis, it is revealed that there are many examples 
when biochemical and morphological characteristics of both apoptosis and necrosis are found in 
the same cell. This indicates that apoptosis and necrosis are just two extremes of a series of cell 
death program that occur in a dying cell. Furthermore, apoptosis is considered as a process of cell 
elimination without disruption of the plasma membrane, while necrosis is the result of rapid 
efflux of cell constituents into the extracellular space. However, it is reported that in vitro 
apoptosis finally leads to the disruption of plasma membrane due to absence of phagocytosis. 
Members of the TNF (tumor necrosis factor) receptor family Fas, and TNF-related apoptosis-
inducing ligand (TRAIL) not only initiate apoptosis but also necrosis [147,148]. RIP 1 is a death-
domain-containing kinase associated with the death receptors that is required for activating 
necrosis by the death receptor ligands (FasL or TNFα) [147]. Another important sensor is massive 
DNA damage brought about due to excessive ROS production. Excess of DNA damage activates 
Poly (ADP-ribose) polymerase (PARP), thus depleting ATP and activating necrosis due to energy 
depletion [149,150]. PARP is a nuclear enzyme activated in response to excessive DNA breaks. 
Upon activation it binds to oligomers of ADP-ribose, thus utilizing ATP for synthesis of PARP 
substrate NAD
+
, Ca
2+
 ions plays an important role as an inducer and secondary messenger 
involved in receptor mediated necrosis [151]. Mitochondria play a crucial role in determining cell 
fate under stress conditions. It is a source of death promoting factors as it can initiate and amplify 
caspase dependent death pathway by effluxing cytochrome C, or initiate cell death in a caspase 
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independent manner by secreting AIF or EndoG. It also produces ROS that may trigger necrosis 
[152-153]. Being the factory for ATP production, mitochondria chooses between ATP dependent 
and independent processes depending upon its availability for bringing about cell death under 
stress conditions. The anti-apoptotic members of Bcl-2 family (Bcl-2, Bcl-XL) can inhibit both 
apoptosis and necrosis [154-158]. A protein belonging to Bcl-2 family named BNIP3 
(BCL2/adenovirus E1B 19 kDa protein-interacting protein 3) has been discovered possessing 
pronecrotic activity [158]. Stress kinases like JNK (c-Jun N-terminal kinases) and p38 activated 
by ligation of death receptors, oxidative stress and DNA damage have the ability to initiate both 
apoptotic and necrotic programs. Inhibition and suppression of these stress kinases decreased 
necrotic death in many cells [159, 160]. On the other hand, stress induced apoptosis protected by 
AKT kinase and MAP kinase ERK can also provide protection against necrotic cell death [161-
164]. This indicates that proapoptotic (JNK and p38) and antiapoptotic (AKT and ERK) function 
in similar manner in necrosis (Figure 2).  
Finally, the terminal step of necrosis is the activation of proteases. Caspases may or may not be 
involved in the execution stage of necrosis as it has been observed in many cases that inhibition of 
caspases during stress conditions may trigger necrosis. Calpains, cathepsins and serine proteases 
are the main proteases involved in necrosis [165].  
Besides apoptosis and necrosis, autophagy has also an important role in cell death machinery. 
Autophagy is a degradative process where cyoplasmic organelles are hydrolysed to provide 
metabolic precursor to fulfill the energy demand of the cells which are under stress condition such 
as starvation. Though, initially it is believed that autophagy plays an important role in cell 
survival by elimination of damaged organelles, but recently it has been reported that Autophagy 
also kills the cells [166]. This autophagy cell death mechanism is also called as type II cell death 
mechanism. It works as secondary death mechanism when apoptosis death pathways are not 
available. Though apoptosis and autophagy have distinct mechanism of action, but both are 
regulated by each other [167]. 
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2.3.5  New Generation Cryopreservation and Post thaw culture medium 
 
Figure 2: Mediators of apoptosis during cryopreservation and effective apoptosis inhibitors [254] 
LC3B-II protein is the indicator of Autophagy [168]. The unprocessed form of LC3 (pro LC3) is 
proteolytically cleaved by Atg4 protease, resulting in formation of LC3-I ( carboxy terminal with 
exposed glycine).Upon activation of autophagy the LC3-I is conjugated with 
phosphatidylethanolamine (PE) moiety in presences of Atg7, Atg3, Atg12, Atg5 and Atg16L 
multimers to generate LC3-II. LC3-II is the only well characterized protein that is phagophore to 
lysosomal degradation [168]. 
2.3.6 Motivation for cryopreservation of MSCs 
Mesenchymal stem cells (MSCs) are becoming increasingly important source of stem cells that 
have the potentiality to be used for the regenerative and or repair of damaged tissue and thus 
restore the tissue functionality. MSCs have the ability to proliferate and differentiate into a series 
of mesoderm type lineages includes osteoblast/osteocytes [32], chondrocytes [33], skeletal 
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muscles[34], adipocyte and myocytes, vascular cells and the like [35]. With the advancement of 
MSCs isolation and expansion, the development of technology and or strategy for storing and 
preserving of MSCs for long time without change in its properties is of paramount importance so 
that these MSCs can be used when patient needs. The current technique using Me2SO as CPA has 
potentiality for preservation of various cells and tissue. However, the use of Me2SO has 
detrimental effects causing cell death. Me2SO is considered to possess an impact on the genetic 
profile and induce differentiation in murine stem cells[36].  Use of nontraditional cryoprotectant 
in preservation of stem cells a crucial facet because the entire long term storages are done with 
customary Me2SO and glycerol. Several studies have already been done on the cryopreservation 
of mesenchymal stem cell with trehalose and few with ectoin also [13, 37-47]. However, very 
little work has been done on long term cryopreservation of hMSC using natural osmolytes and 
impact of these cryoprotectants on long time storage of MSCs. The aim of our present study is, 
therefore, to investigate the effect of trehalose and ectoin as major cryoprotectant using a reduced 
amount of Me2SO for long term cryopreservation of MSCs. 
 Furthermore, many factors affect the effectiveness of MSCs cryopreservation, including 
incubation temperature, the freezing medium, cooling rate, storage temperature, and cell 
concentration during freezing and duration of storage, thawing temperature, and thawing medium.  
And also the cooling profile which is important for the cell viability is not taken into 
consideration [125].  Long time biopreservation technique that maintains ex-vivo TECs viability 
and functioning is one of the most important research aspects of modern tissue engineering and 
regenerative medicine. The ability to preserve the integrity of TECs outside the native 
environment for an extended period shall not only save time of the donors and the recipients, but 
it may also be possible to establish cell bio-banks worldwide for the safe preservation of high 
quality TECs products for use when need arises. Such a ready to use TECs would support the 
implementation of routine cryopreservation practices during preparation of even engineered cells 
and tissues for the clinical applications when needed. 
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Chapter III 
Scope and Objective 
 
 
 
 
 
 
 
 
 
 
 
Mesenchymal stem cell is an important and promising cell source for various therapeutic 
applications and development of various tissue constructs/tissue grafts through tissue engineering 
approach. Thus there is a worldwide demand of mesenchymal stem cells (MSCs) and MSCs 
seeded scaffold (TECs) in clinical sector for the treatment of variety of blood and tissue related 
diseases. With the advancement of isolation and expansion of MSCs and development of  tissue 
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engineering products utilizing MSCs as an important cell source, the development of technology 
and/or strategy for storing and preserving of such clinical products for long time without change 
in their properties is of paramount importance keeping in view of their actual use when patient 
needs. Cryopreservation has been found to be the most effective method of preserving cells using 
Me2SO as CPA. However, the use of Me2SO in cryopreservation medium cause cell death and 
also harmful to the patient.  
In this context, one of the key challenges is the development of a cryopreservation strategy using 
an alternative freezing medium that can preserve MSCs and MSCs seeded scaffold for a longer 
period of time with high recovery of cells, differentiation ability and structural integrity of the 
scaffold used in TECs formation.  
Therefore, the main objective of the present research is the development of cryopreservation 
strategy using natural osmolytes for long term cryopreservation of MSCs and MSCs seeded 
scaffold.  
The specific objectives of the present research work are as follows: 
1. To select potential non-toxic (natural) cryoprotective agents  
2. To evaluate the potentiality of natural osmolytes in preserving MSCs 
3. To study the role of apoptosis pathways in cryopreserved induced cell death of MSCs 
4.  To optimize the controlled rate freezing condition for cryopreservation of MSCs using natural 
CPAs 
5. To evaluate the potentiality of natural CPAs in preserving MSCs seeded constructs 
6. To optimize the controlled rate freezing MSCs seeded constructs using natural CPAs 
 
 
Scope of work 
Cryopreservation is proven to be an efficient method for preserving varies of cells and other 
biological species. This method uses Me2SO is as a potential CPA which is reported to have 
several detrimental effect causing cell death. To overcome the limitation and adverse effect of 
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Me2SO, the recent research is directed towards the search of natural CPAs which seem to be 
promising without having harmful effect like Me2SO. However there is very limited research has 
been done on the study of these natural osmolytes for its actual use in long term preservation of 
MSCs and other clinical product using MSCs.  
Therefore the present investigation aimed to formulate efficient cryopreservation medium from 
potential natural CPAs for preserving MSCs and develop a cryopreservation system that will be 
helpful to preserve MSCs and other tissue products on long term basis. 
The specific scope of work under this research includes the following 
1. Selection of potential CPAs alternative to Me2SO 
In this part, efforts would be given to select a single or a combination of potential natural 
cryoprotective agents by a preliminary study on cryopreservation of umbilical cord blood (UCB) 
derived MNCs in a controlled rate freezer. Different batches of cryopreservation solutions 
prepared using extracellular cryoprotectants like trehalose, hydroxyl ethyl starch, polyvinyl 
pyrrolidine and intracellular CPAs like erythritol, taurine and ectoin will be investigated and the 
most effective CPAs will be selected for further study on cryopreservation of MSCs.  
The formation of reactive oxygen is another important factor which causes cellular damage during 
low temperature storage. In this context, the addition of selective antioxidants in cryopreservation 
medium is reported to be beneficial to overcome this oxidative effect and thus improve post-thaw 
cell viability. Keeping this in view, cryopreservation experiments will be performed to investigate 
the performance of the best obtained freezing solution in presence of potential antioxidants such 
as catalase, co-enzyme Q10 and N-acetyl cystine and thus an optimal freezing solution is 
expected to be obtained giving maximum cell viability after cryopreservation.   
2.  Development of an effective freezing solution for cryopreservation MSCs  
This phase of research will focus on the development of a freezing solution from the selected 
CPAs and antioxidant for long term preservation of MSCs. Different batches of freezing solutions 
will be prepared using individual as well as combination of selected CPAs. The solutions will be 
evaluated by cryopreservation experiment to see their ability towards preserving MSCs and the 
most effective freezing solution will be selected.    
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3. Study on apoptosis signaling pathways  
Apoptosis that involves program cell death is an important phenomenon that occurs in 
cryopreserved cells. The inhibition of cryopreserved induced apoptosis is important to improve 
the post thaw viability of cryopreserved cells. Therefore, an effort will be given to study the 
influence of important caspase and calpain inhibitors on the cryopreservation of MSCs and the 
potential inhibitors will be selected to improve further the effectiveness of the developed freezing 
solutions. 
4.  Optimization of cryopreservation condition for MSCs 
The controlled rate freezing condition will be optimized further by studying  the effect of key 
parameters such prenucleation cooling rate, nucleation temperature, cold spike temperature, post 
nucleation holding temperature, post nucleation cooling rate, cell concentration and storage 
temperature using the best obtained freezing solution to maximize the MSCs recovery 
5. Evaluation of developed freezing solution for preserving MSCs seeded scaffold  
In this phase, research work will further be extended to evaluate the potentiality of the freezing 
solution developed for MSCs cryopreservation towards the preservation of TECs formed from 
MSCs seeded on scaffold. 
6.  Optimization of cryopreservation condition for TECs 
The controlled rate freezing condition will be further optimized by studying the effect of key 
parameters such as prenucleation cooling rate and nucleation temperature using the best obtained 
freezing solution to maximize the MSCs recovery in TECs 
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Chapter IV 
Materials & Methods 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
4.1 Chemicals and culture media 
4.1.1 Cryoprotective agents  
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The various cryoprotective agents such as trehalose, Me2SO, hydroxy ethyl starch (HES), ectoin, 
erythritol and poly vinyl chloride (PVC) used in this thesis work were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). 
4.1.2 Antioxidants and inhibitors   
The chemicals such as co-enzyme Q-10, ascorbic acid, catalase and N-acetyl cystine were 
purchased from Sigma Chemical Co. (St. Louis, MO, USA) and used as antioxidants. Caspase 
inhibitors (z-LEHD-FMK, z-IETD-FMK, z-DEVD-FMK, z-VAD-FMK) and calpain inhibitors 
(3-(4-iodophenyl)-2-mercapto-(Z)-2-propenoic acid) were purchased from BD pharminogen 
(Becton Dickenson, San Jose, CA, USA). 
4.1.3 Cell culture media and antibodies  
Dulbecco’s modified eagle medium (DMEM), Penicillin-Streptomycin solution, fetal bovine 
serum (FBS), Dulbecco’s phosphate buffered saline (DPBS), chondrogenic basal medium and 
supplement, Collagenase type I and 0.25% Trypsin /ethylene diamine tetra acetic acid (EDTA) 
solution were procured from Gibco (BRL, USA). Phalloidin-Alexa Fluor 488 conjugate, calcein 
green AM and JC1 were used of Invitrogen, USA. Ficol Hypaque solution (Hi sep LSM 1073), 
adipogenic differentiation media, Giemsa 10x stain, Triton X-100, formaldehyde, reagent for 
MTT assay and Commassie blue G-250  are of HiMedia labs, India. Growth factors EGF and 
bFGF, BD FACS lysis buffer, propidium iodide (PI), CD34-PE, CD44-FITC, CD45-PerCP/cy5.5, 
CD73-PE/APC, CD90-APC, CD105-PE and HLA-DR-PerCP/cy5.5, Annexin-V conjugated with 
FITC were from BD pharminogen (Becton Dickenson, San Jose, CA). Dexamethasone, 
staurosporine, α-MEM, L- glutamine, L-ascorbate, β-glycerophosphate, bovine serum albumin 
(BSA), Oil red O, Alizarin red S, Safranin O were from Sigma-Aldrich (St Louis, MO, USA). All 
the tissue culture plastic wares and RNase were from BD falcon and MP Biomedicals, USA, 
respectively.   
 
 
4.2 Collection and processing of umbilical cord blood 
Umbilical cord blood (UCB) samples were collected from Ispat General Hospital, Rourkela, India 
with prior consent of the full-term delivery patients. A blood collection bag containing 17 ml of 
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citrate phosphate dextrose adenine (CPDA) anticoagulant was used for aseptic transfer of the cord 
blood sample each time and brought to our culture laboratory for processing. The Institutional 
ethical board approved the collection procedure.  
4.3 Isolation and culture of MNCs 
The MNCs were isolated from umbilical cord blood by standard Ficol hypaque density gradient 
method [33]. 30 ml of cord blood sample was diluted with RPMI 1640 in the ratio of 4:1 (v/v) and 
added to 20 ml of ficol hypaque solution. The solution is then centrifuged (swing bucket rotor) at 
430×g for 30 min at 4°C. From the three layers formed, the middle layer (buffy coat) containing 
MNCs was separated, followed by the addition of 1x Lysis buffer (1:9 dilution of 10x stock buffer 
in distilled water) and incubated for 10min at room temperature. The cell suspension was 
centrifuged at 200×g for 10 min at 4°C and supernatant was discarded. The pellet was washed to 
remove lysis buffer and other impurities by centrifugation twice with D-PBS at 200×g for 10 min 
each time. Finally the pellet obtained was resuspended in expansion medium consisting of α-
MEM, 10% FBS, 2mM glutamine and 1% antibiotic-antimycotic solution and plated at density of 
1×10
6 
cells/cm
3
. The non adherent cells were discarded after incubating culture plates at 37°C 
with 5% humidified CO2 for 24 h. The adherent cells were washed thoroughly with D-PBS/EDTA 
and then supplemented with freshly prepared expansion medium. The cells were cultured with 
media change weekly twice.  
4.4 Sorting and culturing of MSCs 
Mesenchymal stem cells (MSCs) were isolated from the cultured human mononuclear cells 
(hMNCs) by florescence activated cell sorting (FACS ARIA III; BD Biosciences) using 
antibodies like CD90-APC, CD73-APC, CD105-APC, CD44-FITC, CD45 PerCP Cy5-5, HLA-
DR PerCP Cy5-5, CD34 PE. UCB derived MSCs was isolated from MNC populations by positive 
selection using CD44, CD90, CD73vand CD105 positive antibodies (BD Biosciences, USA). 
After sorting, the cells were counted by haemocytometer with Trypan Blue dye used for staining 
dead cells. MSCs were suspended in an expansion medium consisting of Dulbecco's modified 
eagle medium (DMEM), 10% FBS and 1% antibiotic-antimycotic solution and plated initially at 
cell density of 1x10
6
cells/cm
3 
in T50 culture flasks (Beckon Dickinson, San José, CA, USA). Non 
adherent cells were discarded after incubating culture plates at 37°C with 5% humidified CO2 for 
24 h. The adherent cells were washed thoroughly with D-PBS/EDTA two or three times and then 
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supplemented with freshly prepared culture media. Thereafter the media was changed twice 
weekly.   
4.5 Characterization of cells 
4.5.1 Morphological characterisation 
MSCs were harvested and morphology was observed from the culture ﬂask under phase-contrast 
inverted microscope. Images of MSCs were captured using a Carl Zeiss Axiovert 40 microscope. 
No speciﬁc staining was carried out. 
4.5.2  Immunophenotypic characterisation 
The specific surface antigens expressed by MSCs were characterized by flow cytometry analysis. 
The trypsinized post-thaw cells (5 × 10
5
 cells per sample) were stained with human monoclonal 
antibodies against CD44, CD45, CD73, CD90, CD105, CD34 and HLA-DR. The CD expressions 
were analyzed using a flow cytometer (Becton Dickinson and Co, San Jose, CA, USA). 
4.6. Cryopreservation of cells  
4.6.1 Preparation of cryopreservation solution 
1×10
6 
cells/ml MNCs were transferred into standard 1-ml cryovials (Nalge Nunc, IL, USA) 
containing each batch of freezing solutions prepared from 10mM extracellular cryoprotectant, 
5mM intracellular cryoprotectant and 100μg of antioxidant in FBS at 6ºC. The concentrations of 
CPAs were selected based on the published literature [169-173]. Each time, MNCs were treated 
with intracellular cryoprotective agents for 20mins followed by the treatment with extracellular 
cryoprotectants for 10 mins. Similarly, MNCs were resuspended in 10% Me2SO culture medium 
solution without FBS at 4°C as a positive control. For the culture of MSCs, medium was replaced 
with DMEM containing ectoin and trehalose at 0.3 M concentration each and cultured at 37 °C in 
CO2 incubator for overnight [174]. All freezing vials contained 1ml of final freezing medium after 
the addition of cells. Different molar concentrations of osmolytes were added to the cryovials. In 
all cases, 100μg/ml catalase was added to the cryovials. Cryopreservation solution used for this 
study was prepared by adding different concentration of molar ration of trehalose, ectoin and 
100 μg/ml catalase. 
4.6.2 Cryopreservation experiments 
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The sealed cryovials containing each cryoprotectant solution and cells were placed in a controlled 
rate freezer (Kryo360-17, Planer, Inc.., UK) as shown in Figure 3. The cryopreservation 
experiments were carried out following the programmable cooling protocol [175] as- ramp 1, for 
4ºC for 10min; ramp 2, -3ºC/min to -10ºC/min; ramp 3, -15ºC/min to -30ºC/min; ramp 4, -
3ºC/min to -60ºC; Ramp 5, -10ºC/min to -180ºC. After achieving -180°C, the cell suspension was 
taken out of the freezer and stored in vapor phase storage tank (-180 ºC) for further use. Each 
batch of experiments was repeated three times.  
 
 
Figure 3: Controlled rate freezer for cryopreservation of MSCs 
4.6.3 Thawing and post-thaw culturing 
The cryopreserved cells were thawed by immersing cryovials rapidly in water bath at 37°C and 
then subjected to gradual dilution of cryoprotectant solution with prewarmed thawing medium 
(DMEM + 10% FBS). The cells were then centrifuged at 200×g for 5 mins and resuspended in 
DMEM supplemented with 10% FBS, 100U/ml penicillin G, 100 mg/ml streptomycin and 
10ng/ml epidermal growth factor (EGF). The cells were then cultured in 6-well tissue-culture 
plates at 37ºC in a humidified atmosphere of 5% CO2 [177, 178]. 
4.6.4 Cell viability assay 
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After 24h of incubation, medium containing the dead cells were separated and the attached cells 
were trypsinized. All the cells were stained with propidium iodide (PI) and analysed by flow 
cytometry for cell viability. Flow cytometry analysis was done within 10min trypsinization [176].   
4.6.5 Cell proliferation assay 
1×10
4
/ well of cell were seeded into 96-well plates with 100µl of growth medium that consists of 
DMEM supplemented with 10% FBS, and 10ng/ml EGF and incubated at 37ºC and 5% CO2. 
These cells were detached with trypsin/EDTA mixture and the cell number counted from day 1 to 
7 day. The number of viable cells was counted using automated cell counter with cells stained 
with 0.2% trypan blue [177]. 
4.6.6  MTT assay 
The cell viability of cryopreserved cells was further verified by MTT (5-dimethylthiazol-2-y1]-2, 
5-diphenyl tetrazolium bromide) assay using standard micro plate absorbance reader [178].  Post 
thaw cryopreserved MNCs was treated with 10% Me2SO (control) to determine baseline cell 
viability. For viability tests of different batches of CPA solutions, the post thaw cells at 
concentration of 1×10
5
 cells/ml were plated (in triplicate) by adding 10µl MTT solution in each 
well and incubated at 37ºC for 4h in 5% CO2. The optical density of the solution is then measured 
using ELISA plate Reader (Perkin Elmer) at 570 nm. 
4.6.7 Apoptotic assay 
Post-thawed MNCs were labeled with AV-FITC (Annexin V conjugated with FITC) as per 
manufacturer’s instruction (BD Pharmingen, San Diego, CA) [179] and 1×106 cells/ml were 
suspended in PBS (pH 7.4) supplemented with 2mM CaCl2 solution. AV-FITC binding was 
analyzed with respect to fresh cells as positive control. The cells were incubated with AV-FITC 
for 15 min in dark at room temperature and then subjected to flow cytometry analysis using 
FACS Aria III flow cytometer (Becton Dickinson, San Jose, CA). For each sample, 10,000 events 
were acquired from the region defined for MNCs and analyzed by BD FACSDiva Software 6.0 
(Becton Dickinson, San Jose, CA). Compensation was required for the annexin V assay. Firstly, 
this was done by analyzing an autoﬂuorescent control to determine the level of autoﬂuorescence. 
Secondly, annexin V-FITC labeled cell population was analysed to establish optimal 
compensation for annexin V-FITC. Finally, only PI-labeled cells were analyzed on these settings 
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and the cell populations was recompensated by subtracting the overlapping of PI and FITC. Cells 
cryopreserved with 10% Me2SO (v/v) were used as negative control.  
4.6.8 Mitochondrial membrane potential assay 
Mitochondrial membrane potential of cryopreserved MSCs were evaluated by flowcytometry 
using JC-1 as per method previously described [180]. Post thaw cryopreserved MSCs for 12 
month were exposed to JC-1 for 15min at 10μg/ml concentration in culture medium and incubated 
in 5% Co2 at 37°C. For the assessment of JC-1 staining, a total of 10,000 gated events were 
analyzed per sample. In addition, the entire samples were viewed by fluorescence microscopy to 
confirm JC-1 labeling. 
4.6.9 Differentiation potential 
After 12 months of storage in vapor phase liquid nitrogen, the cryopreserved MSCs were thawed 
by usual procedure. Both cryopreserved and fresh (non-cryopreserved) MSCs were then seeded at 
a concentration of 3×10
3
 cells/cm
2 
into a 6 well-plates coated with type I collagen and cultured in 
DMEM medium supplemented with 10% FBS for 24h. 
Osteogenic differentiation 
The osteogenic differentiation ability of cryopreserved MSCs was assessed by following the 
method described in literature [181]. The differentiation of hMSCs were induced by culturing 
with osteogenic differentiation medium consisting of DMEM supplemented with 100nM 
dexamethasone, 0.05µM ascorbate-2-phosphate, 10mM β-glycerophosphate, 1% 
antibiotic/antimycotic and 10% FBS for 14 and 21days. The culture medium was replaced twice a 
week. After a specific period of culture, cells were washed twice with PBS and fixed with 2% 
methanol for 10 min at room temperature. The cells were then stained with 1% alizarin Red S for 
15min and used for assessment of mineral deposition. 
Adipogenic differentiation 
For the assessment of adipogenic differentiation potential, cryopreserved and unfrozen hMSCs 
were cultured in adipogenic differentiation medium. The medium contains DMEM supplemented 
with 10% FBS, 0.5 Mm isobutyl-methyl xanthine, 1µM dexamethasone, 10 µg/ml insulin, 200 
µM indomethacin, and 1% antibiotic/antimycotic. The culturing was done for 7 and 14 days with 
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the change of media twice a week. The cells were washed with PBS and then fixed with 2% 
methanol. The cells were stained with oil red O to visualize the intracellular lipid droplets.  
Chondrogenic differentiation 
The chondrogenic differentiation of post thaw cultured cells was performed using pellet culture 
method as previously described [181]. Briefly, 2.5×10
5
 cryopreserved and non-cryopreserved 
hMSCs were centrifuged at 800rpm for 15min. The pellets were resuspended in chondrogenic 
differention medium, the composition of which is DMEM supplemented with 10% FBS, 1% 
penicillin, 1% insulin-transferrin-selenium, 10
-7
M dexamethasone, 150µM ascorbic-2-phosphate, 
20 µM linoic acid and 0.1ng/ml TGF-β. The cells were incubated at 37ºC and 5%CO2 
environment for 21days. The chondrogenic culture medium was replaced twice a week. The cells 
were washed in PBS and fixed with methanol before staining with Saffranin O.  
4.6.10 CFU-F assay 
Colony forming assays were done following the procedure described in publish literature [182].  
Post thawed as well as non cryopreserved MSCs were seeded in 75 cm
2
 tissue culture flasks at a 
concentration of 8 cells/cm
2
 in cell culture medium. The medium was changed every 2 to 3 days. 
After 12 days, cells were washed with PBS and fixed with methanol for 15 min. CFU-F colonies 
were stained with 0.4%w/v Giemsa (diluted with deionized water for 30 min) and the culture 
plate was observed under optical microscope (Leica DM750 equipped with digital camera). 
Colonies were considered as clusters of more than 50 cells. 
4.6.11  Cell cycle analysis 
Post thaw MSCs were fixed with the addition of 70% ethanol and stored at 4°C. The ethanol-
suspended cells were centrifuged at 300 g for 5 min and the pellet was suspended in 2 ml of D-
PBS. This pellet was centrifuged again to remove any ethanol and finally the pallet was 
suspended in 1ml D-PBS/EDTA containing 20 μg/ml PI and 100 μg/ml RNase A for 30 min. 
Cells were then analyzed by flow cytometry by gating on PE-area versus PE-width discriminating 
all the doublet population [183].  
4.6.12 Western blotting 
Cryopreserved MSCs were suspended in buffer containing 20 mM TRIS, 2 mM EDTA, 150 mM 
NaCl, 0.5%Triton X-100 and protease inhibitors (Sigma). The samples were sonicated, 
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centrifuged and the pellets were discarded. The cryopreserved MSCs were assayed for protein 
concentration following standard Bradford assay. Protein extracts of 50μg/sample, control or 
post-thaw cryopreserved MSCs were separated on 10% SDS PAGE and transferred to PVDF 
membrane. The membranes were incubated with primary antibodies such as caspase-3 (1:1000, 
BD Biosciences), caspase-8 (1:250, BD Pharmingen), caspase-9 (1:250, BD Pharmingen), 
cytochrome C (1:250, BD Pharmingen), PARP (1:500, BD Pharmingen), Bid (1:250, BD 
Pharmingen) and calpain (Cell Signaling Technology, Inc., Beverly, USA) for overnight [185]. 
The membranes were then incubated with HRP Goat anti-mouse Ig, following the manufacturers 
recommended protocol and visualized on film with the ECL substrate (Abcam Inc., Cambridge, 
MA, USA). 
4.6.13 Optimization of cryopreservation process 
The cryopreservation of MSCs was optimized by investigating the effects of five aspects of 
cryopreservation cooling profile, storage temperature and cell concentration on cell viability. The 
cryopreservation experiments were carried out using (Kryo Cooler 1.6 Planner Biomed, U.K). 
The various controlled rate freezing parameters investigated are: prenucleation cooling rate 
(1ºC/min, 2.5ºC/min, 5ºC/min, and 10ºC/min), holding temperature (0ºC, -2.5ºC, -5ºC, -7.5ºC and 
-10ºC), nucleation temperature (-2.5ºC,-5ºC, -7.5ºC and -10ºC), cold spike temperature (-20 ºC, -
40ºC, -60ºC, -80ºC) and post nucleation cooling temperature ( 1ºC/min, 2.5ºC/min, 5ºC/min, 
10ºC/min). Various MSCs concentrations were compared at 0.5, 1, 3, 6×10
6
 /ml. To select 
optimal storage temperature, final storage temperature was maintained at -80°C, -150°C, or -
196°C. For all experiments, in addition to comparing their own conditions, the medium 
composition used as 0.3M trehalose, 0.3M ectoin, 100μg/ml catalase and 50µm/ml of calpain 
inhibitor (PD 150606) and general caspase inhibitor (z-VAD-fmk) each. The cooling rate of 
1°C/min, storage temperature of −180°C and cell concentration of 2×106 /ml. were maintained. 
4.7 Cryopreservation of TECs 
4.7.1 Preparation of scaffolds 
3-D nanofiberous mats developed using semi automated electrospinning machine (ESPINNANO 
M/s. Physics Instruments Company, India) was used as scaffold for TECs formation. The detail 
description of the method is reported in our patent filed (Patent number: 713/KOL/2012). In brief, 
Silk fibroin (SF) was extracted from eri and tasar silk cocoon by degumming method using aq. 
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Na2CO3. SF blend were prepared and made electrospinnable by dissolving silk fibroin of eri and 
tasar silk in achloroform and formic acid mixed in a ratio of 60:40v/v. The blend was electrospinned 
at 15kV to generate nanofibrous scaffold of thickness 300µm and the average fiber diameter of 
nanofiber is measured as 350nm (range 200-500nm). The contact angle and porosity were 
determined as 54.7º and 80-82%. 
4.7.2 Formation of TECs 
The nanofibrous sheets of dimension 6mm diameter and 400µm thickness were used in this study. 
The scaffolds were autoclaved and then sterilized with 70% EtOH. The sample was further exposed 
to ultraviolet irradiation for 40min to avoid any morphological change. The sterilized scaffolds were 
washed thoroughly with PBS and neutralized with growth medium at 37°C and 5% CO2. 5.0×10
5
 
[48-49] cells/ml (MSCs) were seeded on scaffold by static method and cultured in DMEM 
containing 10% MSC qualified fetal bovine serum and 1% antibiotics for a period of three weeks. 
4.7.3 Preparation of cryopreservation solutions 
Cryopreservation solutions were prepared with varying compositions as follows: (1)10% (v/v) 
Me2SO with 50% (v/v) fetal bovine serum (D10) and T30/E30/C100. All solutions were prepared with 
DMEM media.  
4.7.4 Cryopreservation experiment 
The precultured TECs were exposed to cryoprotectant solutions for 10 min at 4°C and then 
transferred to a high-density polypropylene sterile pouch. The cryopreservation study was performed 
in the computer-controlled programmable freezer following two steps cooling (shown in Figure 4). 
TECs samples were cooled at the rate of 1°C/min down to -150°C and then immersed into liquid 
nitrogen bath [186,187]. After 7 days of cryopreservation, the samples were removed from liquid 
nitrogen and were thawed by shaking at 37°C. The TECs were transferred from pouch into a 35-mm 
culture dish containing DMEM solution and washed thoroughly to remove cryoprotectants from 
TECs. Precultured TECs without cryopreservation was used as control. 
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Figure 4: Controlled rate freezer for cryopreservation of TECs 
 
4.7.5 Characterization of TECs 
4.7.5.1 Cell morphology by SEM 
Scanning electron microscopy was performed before and after cryopreservation at a specific interval 
of time. Cryopreserved TECs were ﬁxed in 2.5% glutaraldehyde at 4ºC overnight. TECs were 
washed three times with deionized water and serially dehydrated with increasing gradient of ethanol. 
Then samples were subjected to SEM study at 15kV accelerating voltage[180-181]. Elements, 
especially calcium (Ca), phosphorous (P) and oxygen (O) on the surface of post-thawed TECs after 
culture for 28days in osteogenic media were analyzed by energy-dispersive X-ray spectroscopy 
(EDX, Philip Model XP 30 CP).  
4.7.5.2 Cell viability 
After cryopreservation study, TECs were removed from DMEM medium and washed twice with 
PBS buffer. MSCs were removed from TECs by treating with 0.25% trypsin and 1mM EDTA. The 
cells were then centrifuged at 200×g for 5 mins and resuspended in PBS. The percentage viability of 
cells was assessed by flow cytometric analysis using propidium iodide [190] staining. 
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4.7.5.3  Cell metabolic activity 
The metabolic activity of MSCs in scaffolds were quantitatively determined by MTT (3-(4, 5-
dimethylthiazol-2-yl)-diphenyltetrazolium bromide formazan) assay at an interval of 3, 5 and 7 days 
of culture period. Culture medium was aspirated and washed with 600µl prewarmed DPBS. 400µl 
prewarmed culture medium supplemented with 40µl MTT solution [2.5mg/ml MTT dissolved in 
Dulbecco's Phosphate Buffered Saline (DPBS)] was added to each sample. After 3hr incubation at 
37°C, the medium was removed from each well and scaffolds were transferred to 24-well petri dish. 
250 µl Me2SO was added to each well to dissolve the formazan crystals[191-192]. The resulting 
solution was removed and centrifuged at 500g. The optical density of the supernatant was measured 
spectrophotometrically at 595 nm, using an ELISA plate Reader (Perkin Elmer).  
4.7.5.4  Cytoskeleton analysis by confocal microscopy 
Post-thaw TECs were fixed with 2% paraformaldehyde in PBS at room temperature for 5min. This 
was followed by 40-min treatment with 2% Bovine serum albumin (BSA) and 1% glycine in PBS to 
block any non-specific staining. Samples were then permeabilized with 0.5% Triton X-100 in PBS 
for 15 min. For actin staining, samples were incubated with Alexa-Fluor 488 conjugated phalloidin 
at 37
0
 C for 40min. in dark condition. Samples were mounted on glass slides and confocal images of 
the samples were acquired using Leica TCS SP5 X Super continuum Confocal Microscope [193-
194].  
4.7.5.5   Osteo-induction assessment 
The osteogenic differentiation potential of cryopreserved TECs was assessed and compared with 
control. Cryopreserved and non cryopreserved TECs were cultured in osteogenic medium consisting 
of high glucose–DMEM (Gibco, Invitrogen) supplemented with L-ascorbic acid-2-phosphate 
(50mg/ml), β-glycerophosphate (10 mM), and dexamethasone (100nM) (Sigma) 24 hr after 
cryopreservation [196-197]. Culture media was allowed to change every 3 days.  
4.7.5.6  Alkaline phosphatase activity 
The alkaline phosphatase (ALP) activity of post thawed TECs was determined quantitatively by 1, 7, 
14, and 21days [195] of TECs culture. The cell lysate from cryopreserved TECs was prepared by 
treating TECs with 1% Triton X-100 for 50 min and sonication for 10 min. The cell lysate is then 
added to ALP substrate (para-Nitrophenylphosphate) with a ratio of 1:1. After 40 min of incubation, 
1 M sodium hydroxide (Sigma) was added to block the enzymatic reaction. The OD of the solution 
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mixture was measured at 405nm in a microplate spectrophotometer. Each experiment was performed 
in triplicate. 
4.7.5.7 Histological study 
The mineralization of hMSCs on the scaffolds was analyzed and quantiﬁed by alizarin red-assay. 
The cells grown on the scaffolds were washed with PBS and fixed with paraformaldehyde for 
15min. The cell-seeded constructs (TECs) were thoroughly washed with distilled water prior to the 
addition of 500ml of 40mM alizarin red stain (pH 4.1). The plates were incubated at room 
temperature for 20 min with gentle shaking. After aspiration of un-incorporated dye, the wells were 
washed thoroughly with distilled water with stirring for 5 min. The plates were left for 2 min to 
facilitate removal of excess water. 
4.7.5.8  Osteogenic-speciﬁc gene expression 
RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) according to the instructions of 
manufacturer. After the treatment of cell extract with DNase (Invitrogen), 1 μg of total RNA was 
used for cDNA synthesis (Superscript First-strand synthesis system, GibcoBRL, Life Technologies) 
following the protocol of manufacturer. RT-PCR was performed to determine the expression of 
genes using primers (Table-3) for the osteogenic differentiation of osteopontin [OPN], ALP and 
core-binding factor alpha 1[Cbfa 1]. Glyceraldehydes phosphate dehydrogenase [GAPDH] was used 
as a house keeping gene for internal control. The polymerase chain reaction (PCR) was carried out 
using BIO-RAD Mycylcer and analyzed by software Bio-Rad. Detail description of the procedure 
described in published literature [195].  
Table  3: The specific primers used for RT-PCR 
Gene  Abbr.  Forward primer  Reverse primer  
Collagenase 2  COL2  GTGGGCTTCCTGGTGA  CAGCACCTGTCTCACCA  
Osteocalcin  OCN  CCCAGGCGCTACCTG TATCAA  GGTCAGCCAACTCGTCACAGTC  
Osteopontin  OPN  TGTGAGCTCAATCCGGACTGT  CCGATAGGCCTCCTGAAGC  
Glyceraldehydes-3-
phosphate 
dehydrogenase  
 GAPDH  GCACCGTCAAGGCTG AGAAC  ATGGTGGTGAAGACGCCAGT  
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4.7.5.9   Mechanical strength 
Scaffolds were subjected to tensile tests before and after cryopreservation for determining their 
elastic modulus, using a Universal tensile testing machine (Instron 4505 Universal Machine) 
following the procedure described in the published literature [197]. The tests were performed under 
compression loading of 1KN with a crosshead speed of 2 mm/min till 60% strain was reached.  
 
4.7.6 Optimization of MSCs cryopreservation parameters 
The precultured TECs were exposed to cryoprotectant solutions for 10min at 4°C and then 
transferred to a high-density polypropylene sterile pouch. The cryopreservation study was 
performed in a computer-controlled programmable freezer (Kryo cooler, UK) following two steps 
cooling. TECs samples were cooled at different cooling rate such as 0.5°C /min, 1°C/min and 
2°C/min from 5°C to -150°C. Finally the scaffold was immersed into liquid LN2 bath. After 7 
days of cryopreservation in vapors phase storages tank, the samples were removed from liquid 
nitrogen and were thawed by shaking at 37°C. The TECs were transferred into a 35-mm culture 
dish containing DMEM solution and washed thoroughly to remove cryoprotectants from TECs. 
Precultured TECs without cryopreservation was used as control. Seeding was performed 
manually at temperature -5° C,-7° C and -10° C to analyze the effect of seeding temperature. 
 
4.7.7 Statistical analysis 
Statistical differences were evaluated by the Tukey-Kramer test after one-way analysis of variance. p 
< 0.05 was considered signiﬁcant using online graphpad quickcalc software. 
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PART I 
A preliminary study on cryopreservation of MNCs: 
Selection of natural cryoprotective agents & antioxidant 
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In recent years stem cell therapy using mesenchymal stem cells has been considered as a 
promising treatment option for patients suffering from various therapeutic and tissue related 
diseases [1-13]. Therefore, systematic efforts have been given by the scientists worldwide for the 
isolation and expansion of MSCs keeping in view of their commercial applications. Umbilical 
cord blood (UCB) is considered as a potential source of MSCs because of its easy availability as a 
waste product, no risk to donor, juvenile source and better proliferation potential compared to 
other sources. However, development of a long term preservation strategy is a prerequisite for 
successful application of MSCs when need arises. Cryopreservation using Me2SO as CPA is a 
proven method for long term storage of human cells with high cell viability and maintenance of 
desired stem cell characteristics [197-200]. However, cellular damage occurs due to extracellular 
and intracellular ice formation and toxicity effect.of using Me2SO. The search for novel 
cryoprotective agent (CPA) as alternative to Me2SO is under active research consideration as 
CPA has a critical role in reducing many of these factors encountered under extreme low 
temperature treatment of cells. 
In this context, treahalose, polyvinyl pyrrolidine (PVP) and hydroxy ethyl starch (HES) seem to 
be attractive extracellular [200-212] and ectoin, taurine and erythritol as intracellular CPAs for the 
preservation of cells [213-219]. These CPAs has important role in protecting cell membrane 
integrity during low temperature preservation by preventing extracellular and intracellular ice 
formation that lead to the damage of cell membrane and denaturation of cell. Furthermore, the use 
of these CPAs in combination seems to be more efficient in preserving cells at low temperature 
freezing conditions [22, 54]. However, not much investigation has been done so far to explore the 
potentiality of these natural CPAs particularly their use in combination for preserving 
mesenchymal stem cells. Another important aspect is that the choices of many CPAs are cell-
specific and their potentiality as CPA cannot be adjudged as a priori. So, in the present study three 
extracellular (trehalose, PVP, HES) and three intracellular (ectoin, taurine and erythritol) CPAs 
were chosen to assess their ability for cryopreservation of MNCs and select the most effective 
CPA which can be further used for the study on MSCs preservation. The MNCs were chosen for 
preliminary trial with intention to avoid the use of MSCs which takes long period of time for their 
harvesting and the process is tedious, whereas MNCs that contains MSCs is easy to isolate and 
handle [220].  
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The formation of reactive oxygen is another important factor which is reported to cause cellular 
damage during low temperature storage. The addition of selective antioxidant in cryopreservation 
medium is reported to improve post thaw cell viability by overcoming this oxidative effect [222]. 
The widely used antioxidants reported are catalase, co-enzyme Q10 and N-acetyl cystine [221-
223]. So the effect of these antioxidants was also investigated to enhance the cryopreservation 
efficiency of the freezing solution. 
5.1.1 Isolation and culture MNCs 
A blood bag containing CPDA solution was used for the CB collections. The blood was collected 
by gravity as shown in Figure 5. The cells isolated by Ficol- hypaqe technique were first cultured 
on plates in DMEM media with supplement of 10%FBS and 1% antibiotic. After 14 days of 
culture, MNCs were harvested using trypsin/EDTA solution (Figure 6).  
 
5.1.2 Cell morphology study 
The morphological variation in the cultured cells was studied by phase contrast microscopic 
images as shown in Figure 7(A-F). After initial culture, the cells are observed to be round in 
shape (Figure 7 A) and MNCs are shown to be adherent to culture plate after 48h (Figure 7B). 
Cells became elongated as spindle fibroblastic shape after 4 days of culture (Figure 7C) and 
confluence is shown to be reached after 14 days of culture (Figure 7F). 
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Figure 5: Collection of Cord blood: (A) Clamped and cut the cord just after the birth of baby, (B) 
and (C)  needle is  inserted in umbilical cord with collection bag, (D) cord blood allowed to ﬁll the 
collection bag by gravity 
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Figure 6:  Schematic representation of isolation procedure of MNC from umbilical derived cord 
blood 
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Figure 7: Phase contrast microscopic images depicting the morphological changes during culture 
period. After initial culture, the cells are observed to be round in shape (A) and MNCs are shown to 
be adherent to culture plate after 48h (B). Cells became elongated as spindle fibroblastic shape after 
4 days of culture (C) and confluence is shown to be reached after 14 days of culture ( F) 
 
 
 
Day 1 Day 2 
Day 3 Day 4 
Day 7 Day 14 
1414 
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5.1.3 Cryopreservation solution  
Different freezing solutions for cryopreservation of MNCs prepared by taguchi orthogonal L9 
array are presented in Table 4.   
 
Table- 4: Taguchi L9 array for nine cryoprotectant solutions with different compositions 
 
 
5.1.4 Cell viability and apoptosis study 
An important phenomenon that occurs in cryopreserved cells is the programmed cell death, called 
apoptosis. The measurement of this apoptosis is important because it permits the detection of cells 
that are undergoing a programmed cell death without disrupting their membrane integrity and thus 
it helps in selection of cryoprotective agents [50-51]. In this study, the cell viability and apoptosis 
of post thaw cultured MNCs were studied by flowcytometry analysis using Annexin–V FITC/PI 
staining. Four quadrants of dot plots consisting of Q1 -dead and necrotic cells, Q2-late apoptotic, 
Q3-live and Q4-late apoptotic are defined as 
Q1-Annexin V-FITC negative & PI positive –dead and necrotic cells,  
Q2-Annexin V-FITC positive & PI positive –late apoptotic cells,  
Q3-Annexin V-FITC negative & PI negative -live cells,  
Cryopreservation solution  1 
A 
2 
B 
3 
C 
4 
D 
Solution-1 HES Erythritol Co-enzyme Q 10 10%  FBS 
Solution-2 HES Taurine Catalase  5%  FBS 
Solution-3 HES Ectoin N-acetyl cystine 0%  FBS 
Solution-4 PVP Erythritol Catalase  0%  FBS 
Solution-5 PVP Taurine N-acetyl cystine 10% FBS 
Solution-6 PVP Ectoin Co-enzyme Q 10 5% FBS 
Solution-7 Trehalose Erythritol N-acetyl cystine 5%  FBS 
Solution-8 Trehalose Taurine Co-enzyme Q 10 0%  FBS 
Solution-9 Trehalose Ectoin Catalase 10% FBS 
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Q4- Annexin V-FITC positive & PI negative-early apoptotic.  
The dot plots of flowcytometry analysis found with post-thaw cultured samples are shown in 
Figure 8 and the cell viability data generated from dot plots is tabulated in Table 5. The 
experimental results indicate that the combination of hydroxy ethyl starch, ectoin, catalase and 
10% FBS (solution-9) has shown maximum cell viability of 93.7%, 5.5% early apoptotic cells, 
0.7% late apoptotic cells and 0.1% necrotic cells. But the combinations of polyvinlypyrrolidine, 
erythritol and co-enzyme Q10 in absence of FBS have shown the least cell viability of 36.0%. 
The cell viability is also compared with the cell viability obtained with the cells cryopreserved in 
10% (v/v) Me2SO as control. The cell viability was observed to be significantly reduced when 
cell cryopreserved in Me2SO. The cell viability achieved in later case is 60%. Percentage of cells 
in Q3 quadrant was further used for Taguchi statistical analysis. Signal-to-Noise ratio (S/N), a 
logarithmic functions of desired output, that serves as objective functions for optimization, helps 
in data analysis and thus predicts the optimum results. There are three way of calculating Signal-
to-Noise ratios (1) smaller-the-better (2) larger-the-better and (3) nominal-the-best. In the present 
study S/N ratio was calculated based on the principle of “smaller the better 
Table 5:  S/N ratio and percentage of cells in Q3 quadrant (viable cell) 
Sample Repetition -1 Repetition-2 Repetition-3 Average viability S/N Ratio 
Solution 1 83.70 84.4 84.2 84.1 47.5817 
Solution 2 66.90 66.3 66.5 66.6 46.9271 
Solution 3 69.90 70.8 67.8 69.6 41.0037 
Solution 4 36.09 35.9 36.3 36.0 51.5668 
Solution 5 68.80 72.0 70.0 70.5 32.8675 
Solution 6 83.50 80.3 81.5 81.6 34.1221 
Solution 7 80.50 79.6 78.0 79.4 42.6865 
Solution 8 63.00 67.0 64.0 65.0 30.2377 
Solution 9 91.60 93.8 95.5 93.7 37.4882 
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Figure 8:Dot plots of cryopreserved and non-cryopreserved MNCs: control(A), cryopreserved 
MSCs in Me2SO (B), HES, erythritol, Co-enzyme Q10 and 10%FBS(C), HES, taurine, catalase and 
5%FBS(D), HES, ectoin, n-acetyl cystine and 0%FBS(E),  PVP, erythritol, catalase and 0% 
FBS(F), PVP, taurine, n-acetyl cystine and 10%FBS(G), PVP, ectoin, co-enzyme Q10 and 
5%FBS(H),   trehalose, erythritol, n-acetyl cystine and 5%FBS(I), trehalose, taurine, co-enzyme 
Q10 and 0% FBS (J),   trehalose, ectoin, catalase and 10%FBS(K) 
 
5.1.5 Statistical analysis   
The S/N ratio data as shown in Figure 9, was calculated based on Taguchi’s smaller the better 
approach (224-225). A large variation in S/N ratio is observed among the extracellular 
cryoprotectants, intracellular cryoprotectants and antioxidants as evident from Figure 2(C1), (C2) 
and (C3). Furthermore, there was no significant variation in S/N ratio observed with the sample 
containing FBS which indicates that variation in concentration of FBS does not have any 
remarkable effect on cell viability. However, though a slightly increase in cell viability is 
achieved with freezing medium containing 5%FBS. Among various cryoprotective agents 
studied, trehalose and ectoin are found to be the most effective extracellular and intracellular 
cryoprotective agents showing maximum cell viability in terms of S/N ratio. Similarly catalase 
was found to be the most favorable antioxidant.  
 
5.1.6 Analysis of Variance (ANOVA) 
 ANOVA helps in testing the significance of all main factors and their interactions by comparing 
the mean square against an estimate of the experimental errors at specific confidence levels 
[225]. The results are also compared with statistical data obtained by ANOVA analysis based on 
analysis of variance as shown in Table 6. Data confirms that the extracellular (p value=0.0003) 
J K 
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and intracellular CPAs (p value=0.009) have greater influence on cell viability compared to other 
factors such as FBS concentration (p value= 0.05) and types of antioxidants (p value= 0.037). 
 
 
 
Figure9: Illustrates S/N ratio averages for each parameter at three levels. As it is observed 
extracellular cryoprotectants (C1) intracellular cryoprotectants (C2) and antioxidants 
concentrations (C3) exhibit larger variations. However, the largest variation is found in case of 
antioxidants 
 
Since the Taguchi Orthogonal array adopted in this study is a factorial experiment, it is necessary 
to conduct verification experiment to ascertain that the entire factor included in this analysis are 
significant [224].Therefore, various experiments for verification under best obtained level with 
the respective factor were performed following the methodology published earlier [225]. The 
average viability is calculated based on flowcytometry as 73% which is shown to be within the 
confidence level, where quadrant analysis shows the distribution of viable MNCs (7AAD -ve, 
Annexin V-ve), apoptotic MNCs (7AAD -ve, Annexin V +ve), and necrotic MNCs (7AAD +ve, 
Annexin V +ve).  
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Table 6: ANOVA analysis of experiments consider in Taguchi orthogonal array 
Factor Degree of freedom Sum of squares Mean square P-value  
Extracellular cryoprotectants 2 129.4 64.7 0.0003 
Natural osmolytes  2 133.5 66.7 0.009 
Antioxidants 2 94.8 47.4 0.037 
Concentration of FBS 2 13.1 6.5  0.050 
Total 8 370.8   
 
5.1.7 Cell morphology analysis of cryopreserved cells 
The cellular morphology of cryopreserved MNCs was studied by SEM and fluorescence 
microscopic images (Figure 10). The cryopreserved cells are observed to retain their normal cell 
morphology. 
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Figure 10: Conformity test for best obtained level with the respective factor. (A) Dot plot of non-
cryopreserved sample (negative control), (B) Post-thaw MNCs  viability, (C) SEM image of after 
24h post-thaw MNCs ,(D) fluorescence image after 24h post thaw of MNCs at 5x magnification. (B), 
(C) and (D) show the result observed with combination of trehalose, ectoin, catalase and 5% FBS 
 
5.1.8 MTT assay 
The cell viability of cryopreserved MNCs was also measured quantitatively by MTT assay and 
the experimental results are shown in Figure 11. The assay result indicates that the cells 
preserved in solution 1, 2, 3, 7 and 9 are more viable after 24 h of post thaw compared to the cell 
viability observed with other CPA solutions. Furthermore, the combination consisting of 
A B 
C D 
74 | P a g e  
 
trehalose, ectoin and catalases have shown better cell viability as compared to the other 
antioxidant present in cryopreserved solution. However, a statistically significant increase in cell 
viability is observed using cryoprotectant solution 9 (***p<0.0005) followed by 3 (**p<0.05) as 
compared to the post thaw MNCs cryopreserved in 10% Me2SO. The result has shown similar 
trend as the results obtained by using flow cytometer i.e apoptosis study. However, cell viability 
with traditional Me2SO treated samples are found to be less as compared to any combination 
except solution 4 (**p<0.05). Furthermore, no significant variation in cell viability is observed 
with solution 5, 6 and 8 from the cell viability achieved with control. 
 
 
Figure 11: MTT assay of post-thawed MNCs cryopreserved in different compositions of 
extracellular cryoprotectant, intracellular, antioxidant and FBS. MNCs cryopreserved in 10% 
Me2SO taken as control. All the data are compared with control using student t-test, Bars represent 
data from three separate experiments with standard deviation (*p< 0.05, **p< 0.005, ***<0.0005)   
 
5.1.9 Post-thaw cytoskeleton assessment 
F-actin, a main constituent of cytoskeleton has an important role in maintaining cellular function 
[226]. It is further reported that at extremely low temperature, the ultra structure of F-actin 
becomes distorted that results in cell damage [227]. Therefore, the effect of cryopreservation was 
investigated using non-toxic CPA solution on the F-actin which would be beneficial to design 
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cryopreservation strategy. The change in F-actin of 48h post thaw cultured samples was observed 
under the florescence microscope (Figure10). Non-cryopreserved cell shows prominent 
cytoplasmaic extension with maximum cell attached to the flask as depicted in Figure 10A and 
MNCs cryopreserved with solution-9 shows good cell attachment. However, the cell attachment 
is found to be lesser than the normal cultured cell (Figure 12B) and higher than the sample 
cryopreserved with 10% Me2SO (Figure 12 C)  
 
       
                                   
Figure 12: Growth and attachment of cryopreserved MNCs after 48 h of incubation. (A) non-
cryopreserved MNCs, (B) MNCs cryopreserved in solution-9 and (C) MNCs cryopreserved in 10% 
Me2SO (Scale bar 100 μm). 
 
 
B A 
C 
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5.1.10 Morphological analysis of cryopreserved MNCs 
The morphology and membrane integrity of cryopreserved MNCs were studied by SEM and 
phase contrast microscopy. Though analysis was done with all samples, but images of non-
cryopreserved MNCs, cryopreserved MNCs with solution-9 and cryopreserved MNCs with 10% 
Me2SO are shown in Figure 13. The MNCs cryopreserved in solution-9 are observed to retain 
their original shape without any bulb formation after 24h of post thaw culturing. This indicates 
that the combination of cryoprotective agents can be used without any adverse effect on the cell 
membrane. Whereas, prominent bulb formation observed in MNCs cryopreserved with 10% 
Me2SO.  
 
 
Figure 13: SEM images of UCB derived MNCs (A) non-cryopreserved MNCs, (B) MNCs 
cryopreserved in solution-9 and (C) MNCs cryopreserved in 10% Me2SO. All the images were 
taken at a magnification of 50X (phase contrast microscope) and 1000X for SEM 
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C 
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5.1.11 Conclusion 
In this study, a number of potential natural osmolytes and antioxidants were investigated to see 
their effects on post-thaw cell viability and early apoptosis of the cryopreserved MNCs isolated 
from UCB. Among the CPAs and antioxidants used under study, trehalose and ectoin as 
extracellular and intracellular CPAs and catalase as antioxidant are found to be the most effective.  
Furthermore, the combination of these CPAs and antioxidant has shown encouraging results 
towards the maintenance and survival of cell during and after freezing achieving maximum post 
thaw viability of 76%, which is more than 10% higher compared to the cell viability obtained 
using conventional Me2SO. Thus it has been demonstrated that trehalose, ectoin and catalase can 
be the major constituents in developing a freezing solution for cryopreservation of MNCs and may 
be useful to develop a cryopreservation strategy for MSCs.  
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PART II 
Cryopreservation of UCB derived MSCs using 
natural cryoprotective agents  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 | P a g e  
 
As it has been already mentioned, transplantation of MSCs derived from umbilical cord blood is 
a promising treatment option for patients suffering from various blood and tissue related diseases 
because of their immunosuppressive properties and ability to differentiate into mesoderm type 
lineages including osteocytes [32], chondrocytes [33], skeletal muscles [34], adipocyte and 
myocytes, vascular cells and the like [35]. This has led to the advancement of isolation and 
expansion of MSCs, for which the development of a successful preservation strategy is of prime 
requirement to advance their clinical applications [59].  
In previous chapter, trehalose and ectoin were found to be the most effective extracellular and 
intracellular natural CPAs and catalase as antioxidant for the preservation of MNCs. In this 
phase of thesis work, the research work has been extended further to evaluate the ability of these 
CPAs and catalase towards preservation of MSCs and establish an optimized controlled rate 
freezing protocol for its long term preservation. 
5.2.1 Sorting and culturing of MSCs 
Fluorescence activated cell sorting allows physical separation of sub-populations of cells of 
interest from a heterogeneous population and thereby a high degree of purity (95-100%) of the 
sorted population is obtained [60]. The cultured MNCs were sorted by this technique using 
CD44, CD73, CD90, CD105, CD34, CD45 and HLA-DR markers. MSCs that are positive to 
CD90/CD105/CD73/CD44 were sorted by cell sorter. As shown in Figure 14(A) primary gate 
applied on FSC-A vs SSC-A to discriminate Mononuclear cells from other population, followed 
by a gate to discriminate singlet from doublet with SSC-H vs SSC-W and FSC-H vs FSC-W 
Figure 14 (B) a gate in FSC-H vs. FSC-W was applied to divide singlet and doublets from higher 
level aggregates, and was refined by similar gate in SSC-H vs. SSC-W (Figure 14C). Singlet 
population was further analyzed for the pattern of expression of CD45/HLA DR vs. CD 34 
(Figure 14D). Negative expressed cells are again gated for CD44 positive cells (Figure 12E). 
Stringent gating was done to remove any false CD44 positive cells based on CD34 vs 
CD45/HLA-DR (Figure 14E). Cells were again gated for true positive CD90/CD73/CD105 cells 
(Figure 14F). 
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Figure24:  Image shows the sorting strategy used for isolation of MSCs. As shown in Figure 14A primary gate applied on FSC-A vs SSC-
A to discriminate Mononuclear cells from other population, followed by a gate to discriminate singlet from doublet with SSC-H vs SSC-W 
and FSC-H vs FSC-W Figure 14 B, a gate in FSC-H vs. FSC-W was applied to divide singlet and doublets from higher level aggregates, 
and was refined by similar gate in SSC-H vs. SSC-W (Figure 14C). Singlet population was further analyzed for the pattern of expression 
of CD45/HLA DR vs. CD 34(Figure 14D). Negative expressed cells are again gated for CD44 positive cells (Figure 12E). Stringent gating 
was done to remove any false CD44 positive cells based on CD34 vs CD45/HLA-DR (Figure 14E). Cells were again gated for true positive 
CD90/CD73/CD105 cells (Figure 14F) 
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5.2.2 Cell morphology study 
After initial culture, cells were observed to be round in shape as depicted in Figure 15 A. After 
48 h of culture cells were shown to be adherent to culture plate (Figure 15B). 
  
  
  
Figure 15: Phase contrast microscopy images showing morphological characteristics of cultured 
hMSCs   A) Initially the cells were round in shape B) Adherent cells after 48 h of culture C) Cells 
became elongated as spindle fibroblastic shape after 4 days of culture D) hMSCs became confluent 
in 14 days  E) hMSCs after passage 1 and F) after passage 2. (Scale bar 100 μm) 
 
Day 1 Day 2 
Day 3 Day 4 
Day 7 Day 14 
1414 
C D 
A B 
E F 
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Further, cells became elongated as spindle fibroblastic shape after 2 days of culture (Figure 15C) 
and cultured cells reached confluence after 4 days (Figure 15D). Cells attains the fibroblastic 
morphology after 1st passage (Figure 15 E & F) 
5.2.3 Immunophenotypic characterization of MSCs 
Isolated MSCs were cultured and colonies were found to appear within 5 to 7 days after initial 
culturing. MSCs were harvested using 0.25% Trypsin/EDTA solution and cells were expanded 
upto passage 4. The cells were then subjected to immunophenotypic characterization by flow 
cytometry analysis, the data (dot plot) of which is shown in Figure 16. The immunophenotypic 
characterizations are shown to be positive for CD90 (99.01%), CD73 (99.5%), CD105 (98%) 
and CD44 (98.5%) expression and negative for CD34 (1.0%), CD45 (0.5%), and HLA-DR 
(1.2%) indicating the cells are mesenchymal stem cells (Figure 16). Immnuoﬂuorescence also 
found to express CD90, and CD105, but not the hematopoietic origin marker CD34 as shown in 
Figure 17. 
 83 | P a g e  
 
 
Figure 16: Flowcytometric analysis on the expression of MSC markers CD90, CD105, CD44, and CD73 as well as hematopoietic markers 
CD34, HLA-DR and CD45  
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Figure 17: Immnuoﬂuorescence observation of passage 4 post thaw MSCs. (A, D) Nuclear staining with 4, 6-diamidino-2-phenylindole 
(DAPI). (B, C) Cell-surface marker CD90 and (E, F) Cell-surface marker CD105. (Scale bar 100 μm) 
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5.2.4 Effect of CPAs on post-thaw MSCs viability 
A series of cryopreservation experiments were conducted in controlled rate freezing equipment 
for the evaluation of the selected CPAs in single as well as in combination for their ability to 
preserve MSCs. The cell viability with post thawed MSCs cryopreserved in various freezing 
solutions prepared from trehalose, ectoin and catalase were measured and the experimental 
results are shown in Figure 18. The result shows that the higher cell viability is observed when 
CPAs are used in combination than the single one. Furthermore, the highest cell viability of 82% 
is obtained with freezing solution that consists of 30mM trehalose, 30mM ectoin and 100µM 
catalase. This freezing solution is designated as T30/E30/C100. No further improvement in cell 
viability is observed with increase in either trehalose or ectoin in the freezing solution. It is also 
demonstrated that catalase has a positive impact on the freezing solution facilitating improved 
cell viability Therefore, it is established that T30/E30/C100 is the most favorable freezing solution 
achieving maximum MSCs viability. 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Effect of CPAs on cell viability of cryopreserved MSCs 
 86 | P a g e  
 
5.2.5 Effect of addition of Me2SO in T30/E30/C100 freezing solution  
 
The effect of T30/E30/C100 0 freezing solution with and without Me2SO was also studied to 
investigate any influence of Me2SO on cryopreservation of MSCs. The experimental data is 
shown in table 7. It is observed that the cell viability of T30/E30/C100 is higher than the cell 
viability obtained with conventional 10% v/v Me2SO. The highest cell viability of 84% is shown 
by T30E30C100 with addition of 2.5%v/v Me2SO.  The cell viability (82%) is comparable to the 
cell viability obtained with T30E30C100 without adding Me2SO. However, keeping in view the 
harmful effect of Me2SO, T30E30C100 is established as the most favorable freezing medium. 
 
Table 7: Effect of Me2SO as an additive in freezing solution on cell viability 
Solution Me2SO      
(%) 
Trehalose 
(mMol/l) 
Ectoin 
(mMol/l) 
Catalase 
(µg/ml) 
Viability  
(%) 
1 0 30 30 100 82 
2 2.5 30 30 100 84 
3 5 30 30 100 75 
4 10 30 30 100 70 
5 10 0 0 0 61 
6 2.5 0 0 0 24 
 
5.2.6. MTT Assay  
The cell viability of cryopreserved MSCs was also evaluated by MTT assay. The assay result is 
shown in Figure 19. It is indicated from Figure that solution containing T30/E30/C100 have 
achieved better cell viability as compared to other freezing solutions tested after 24 h of post 
thaw, though a variation in cell viability is observed among the freezing solutions. The maximum 
cell viability as indicated by slightly higher OD value is achieved with cryopreserved solution 
consisting of a combination of T30/E30/C100 with 2.5% v/v of Me2SO. A comparable cell viability 
is also achieved with T30/E30/C100 freezing solution. Keeping in view the detrimental effect of 
Me2SO, T30/E30/C100 is established as the most favorable freezing medium which is also well 
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supported by the cell viability result obtained by flowcytometry analysis as described in previous 
section.  
 
Figure 19:  MTT assay of post-thawed MSCs cryopreserved in different compositions of 
extracellular cryoprotectant, intracellular, antioxidant with and without Me2SO. MSCs 
cryopreserved in 10% Me2SO taken as control. All the data are compared with control using 
student t-test 
5.2.7 Post-thaw phenotyping characterisation of cryopreserved MSCs 
The phenotyping characterisation of MSCs cryopreserved in T30/E30/C100 with and without 
Me2SO has been done by flow cytometry analysis. CD90, CD44, CD45, CD105, CD73 and 
CD34 expressions of cryopreserved MSCs were measured and compared with control. The 
results are tabulated in table 8. As expected, both cryopreserved and noncryopreserved MSCs 
have shown low expression of hematopoietic stem cell markers CD34, HLA-DR and CD45 and 
high expression of mesenchymal-associated marker CD90, CD73, CD105 and CD44. The 
corresponding positive CD expressions were in the range of 98-99%. Furthermore, there is no 
significant variation in phenotype characteristics are observed with MSCs crypreserved in 
traditional Me2SO. 
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Table-8: Immunophenotypic characterisation of MSCs after cryopreservation 
Cryoprotectant  CD45  CD34  HLA-DR  CD90  CD73  CD105  
T30E30C100  0.60±0.41  0.33±0.26  1.73±37  98.77±31  97.66±78  98.94±37  
T30E30 M10C100  1.36±0.08  0.92±0.48  1.55±33  97.22±71  98.79±24  99.77±66  
M10  0.92±0.22  0.22±0.04  1.49±71  98.88±59  99.06±97  98.45±46  
T30E30M2.5C100  0.60±0.41  0.33±0.26  1.73±37  98.77±31  97.66±78  98.94±37  
T30E30M5C100  1.36±0.08  0.92±0.48  1.55±33  97.22±71  98.79±24  99.77±66  
 
5.2.8 Cell proliferation assessment in cryopreserved MSCs 
As it is expected, non-cryopreserved MSCs are found to proliferate rapidly than 
cryopreserved MSCs [69]. The growth curve of post-thaw MSCs in all freezing solutions 
used in this as well as non-cryopreserved MSCs have shown similar trend i.e. In first 2 days 
after inoculation, no variation in cell number is observed that may be attributed to the 
adherence of cell to the tissue culture plates, and on day 3, the cells entered the logarithmic 
growth stage representing an exponential increase in cell number. The doubling time of 
MSCs in freezing solutions are in the range of 29.0 to 31.9 h (Figure 20 and Table 9). Thus it 
has been demonstrated that MSCs cryopreserved in the newly formulated freezing solution 
T30/E30/C100  has retained their cell proliferation ability.  
 
Figure 20: Growth curves of post thaw hMSCs cryopreserved with T30/E30/C100 and Me2SO       
(10%v/v)  
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Table 9: Population doubling time of MSCs 
Cryoprotectant  Population doubling time (h) 
T30E30C100  29.7 
T30E30 M10C100  31 
M10  30 
T30E30M2.5C100  31 
T30E30M5C100  31.6 
Fresh  29.0 
 
5.2.9 Change of mitochondrial membrane potential in cryopreserved MSCs   
Recent studies have reported a rise in reactive oxygen species (ROS) like superoxide anion 
and hydrogen peroxide during cryopreservation procedure [23]. Mitochondria are considered 
as the main source of this ROS. This superoxide anion induces the release of cytochrome C 
from the intermembrane of mitochondria into the cytoplasm that eventually leads to 
apoptosis. Therefore, ROS suppression using strong antioxidants can be an effective agent 
for improving cell recovery from cryopreserved cells. Furthermore it is reported that the 
generation of ROS and mitochondrial potential are directly correlated [61]. Hence, it is 
important to understand the changes in mitochondria during long term cryopreservation of 
hMSCs. Therefore, the mitochondrial membrane potential (MMP) of MSCs was studied in 
presence or absence of antioxidant using a mitochondrial membrane potential-sensitive dye, 
JC-1. After thawing, cryopreserved cells with and without antioxidant (catalase 100µg) were 
divided into two groups for analysis. The MMP rate was measured as 14±1.2% and 26±2.0% 
for the combination of trehalose and ectoin with or without catalase which is stastically 
significant as shown in Figure 21. Similarly the conventional 10%v/v Me2SO as sole 
cryoprotectant has shown significant variation in MPP with (49±4%) or without (71±10%) 
supplement of catalase. From this study, it has been established that the combination of 
trehalose, ectoin, and antioxidant has very low level of depolarization and 10% v/v Me2SO 
has shown comparatively higher depolarization rate.  
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Figure 21: Analysis of mitochondrial membrane potential (MMP) of post thaw MSCs. At indicated 
time points, cell samples were stained with MMP sensitive dye JC-1. Change in red (polarized) to 
green (depolarized) fluorescence of MSCs was analyzed by FACS, and the data present as dot plots 
to depict percentage of MMP. Staurosporin was added to fresh MSCs as a positive control to induce 
maximum MMP 
5.2.10  Cytoskeleton analysis of post-thaw MSCs 
As it has already been mentioned that F-actin a main constituent of cytoskeleton has a key role in 
the maintenance of cellular function. However, F-actin depolymerises and accumulates during 
low temperature freezing that lead to cell damage [225]. Therefore, it has been investigated the 
effect of cryopreservation on the organization of F-actin. Fluorescence image analysis for change 
in cytoskeleton was done with MSCs treated with different cryoprotectant solutions. However, 
the result obtained with MSCs cryopreserved in most effective freezing solution consisting of 
trehalose, ectoin, and catalase (T30/E30/C100) and traditional 10% v/v Me2SO are shown in Figure 
22. It clearly shows that MSCs frozen in T30/E30/C100 solution retain their original shape without 
undergoing any deformation or damage in F-actin ultra structure after 48 h of post thaw culture 
(Figure 22 C) and similar type of morphology is also shown by control (Figure 22A). Moreover, 
cells have shown normal cell behavior i.e. fibroblast like morphology during post thaw culturing 
which is evident from Figure 22F. In contrast, the distortion in F-actin is observed when MSCs 
are cryopreserved in 10%v/v Me2SO as it is indicated from Figure 22B. A similar type of 
morphology is observed, after 72h of post thaw cryopreserved cells in both 10% v/v Me2SO and 
T30E30C100 as shown in Figure 22D and E. It is further noticed (Figure 22F) that during the 
progress of culture, MSCs frozen in T30/E30/C100 became long shuttle-shaped and on 7 days, the 
occurrence of confluence indicates the start of passaging. Furthermore, cells have shown parallel 
or whirlpool-shaped arrangement on prolonged culturing upto 2, 4 and 8 passages. 
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Figure 22: F-actin morphology and distribution in cryopreserved hMSCs. (A) Fresh 4
th
 passaged MSCs (B) hMSCs cryopreserved 
in 10%Me2SO after 48h post thaw (C) hMSCs cryopreserved in T30/E30/C100  after 48h  post thaw, (D) hMSCs cryopreserved in 
10%Me2SO after 72h  post thaw (E) hMSCs cryopreserved in T30/E30/C100  after 72h  post thaw, (F) hMSCs cryopreserved in T30/E30/C1005  
after 7 days of  post thaw. All the cells were labeled with FITC-phalloidin and visualized by ﬂuorescence microscopy (Scale bar 50 μm
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5.2.11  Effect of storage duration on cell viability  
It is evident from literature that the cell viability immediately after thawing cannot be reliable 
criteria for the evaluation of cryopreservation efficacy. It is reported that the decrease in cell 
viability observed with post thaw sample is related to apoptotic and necrotic processes which 
occur within first 24 hr after thawing process [216]. Therefore the apoptosis assay was done with 
24 hr after post thaw MSCs  at an interval of 1, 6, and 12 months of freezing and was compared 
with fresh MSCs using Annexin/7ADD kit. Freshly isolated MSCs from cord blood were used as 
an experimental control. Results (table 7 and Figure 23) indicate that after 1 month, the freezing 
medium T30E30C100 has shown maximum cell viability of 84.90%, 4.17% early apoptotic cells 
(annexin-V
+
), 5.69% late apoptotic cells (annexin-V
+ 
and 7ADD+) and 5.24% necrotic cells 
(annexin-V
+ 
and 7ADD+)). The corresponding results obtained after six months of 
cryopreservation are 75.74% cell viability, 20.87% early apoptotic, 0.50% late apoptotic and 
2.89% necrotic cells. Comparable result is also obtained with cryopreserved MSCs after 12 
months of storage. The cell viability achieved in later case is 73%. Apoptosis results with 
T30E30C100 are also shown to be encouraging as compared to the result achieved using 
conventional 10%(v/v) Me2SO as freezing medium (Table 10) and a representive data is shown 
in Figure 23. 
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Table 10: Effect of storage time on MSCs viability  
Freezing medium    Storage duration %Viable cells  %Necrotic 
cells  
%Early apoptosis 
cells  
%Late apoptosis 
cells 
 Freshly isolated MSCs  98.04±1.1  0.02±0.005  1.70±0.8  0.24±0.06  
  1 month  84.90±2.5  5.69±0.9  4.17±0.5  5.24±1.7  
T30,E30, C100  6 months  75.74±1.1  2.89±0.12  20.87±0.21  0.50±0.1  
  12 months  73.9±2.3  3.93±1.4  17.07±2.2  3.93±0.3  
  1 month  61.57±3.2  4.54±1.3  24.23±2.1  9.57±1.1  
 10% Me2SO   6 months  51.74±1.7  1.42±0.5  35.86±3.2  10.98±2.5  
  12 months  43.76±2.3  17.37±1.7  20.14±2.6  18.73±1.9  
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Figure 23: Flowcytometric analysis of MSCs apoptosis performed using 7AAD and annexin. The image shows the level 
of viability of MSCs cryopreserved in T30/E30/C100 after (B) 1 month (C) 6 months and (D) 12 months. Similarly, the 
image shows the level of viability of MSCs cryopreserved in 10%Me2SO after  (E) 1 month, (F) 6 months and  (G) 12 
months. Viability of all the samples are compared with freshly isolated MSCs (A) 
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5.2.12  Effect of cryopreservation on differentiation potential of hMSCs 
hMSCs cryopreserved in T30/E30/C100 freezing medium were induced into adipogenic, osteogenic 
and chondrogenic differentiation to examine whether the thawed hMSCs retained their ability to 
differentiate into three specific lineages. The experimental observations are described here- 
Osteogenic potential 
The histological results of the osteogenic differentiation of hMSCs are shown in Figure 24(D, E). 
hMSCs cryopreserved in T30/E30/C100 for 12 months is observed to be sufficiently differentiated 
into osteoblasts as shown by the deposition of calcium on 14 days of culture (Figure 24D). The 
differentiation is stronger on 21 days as it is evident from the deposition of more calcium when 
major portion of the MSCs was mineralized (Figure 24E).  
Chondrogenic potential 
The chondrogenic differentiation of hMSCs cryopreserved in T30/E30/C100 and non cryopreserved 
hMSCs is depicted in Figure 24 (A, B). The cells were stained positive with safranin O indicates 
the formation of cartilage matrix on 14days of culture. The entire well plate is observed to be 
covered with differentiated extracellular cartilage matrix on 21 days (Figure 24B). 
Adipogenic potential  
The histological results of adipogenic differentiation of cryopreserved hMSCs are shown in 
Figure 24 (G, H). When the post thaw MSCs were exposed to the adipogenic medium, the cell 
morphology underwent transition from elongated fibroblast shape into a round or polygonal 
shape. After 14 days of induction, a consistent cell vacuolation is evident in the induced cells 
(Figure 24G). Most of the differentiated cells showed red lipid droplets throughout the cytoplasm 
when stained with 0.36% Oil red O stain as depicted in Figure 24H [64],[36].  
Thus it has been demonstrated that the MSCs cryopreserved in T30/E30/C100 freezing solution has 
retained its adipogenic, osteogenic and chondrogenic differentiation ability even after 12 months 
of cryopreservation.  
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Figure 24: Representative phase contrast images of differentiated and undifferentiated hMSCs.  
Images in first and second column are of differentiated post thaw MSCs cryopreserved in freezing 
medium containing trehalose, ectoin & catalase (T30E30C100).  (A, B) shows differentiation of MSCs to 
osteocytes, (stained with alizarin Red S stain (D, E) differentiation of MSCs to chondrocytes (stained 
with Saffranin O and (G, H) differentiation of MSCs to adipocytes (stained with oil red O) (Scale 
bar 100 μm), Images in third column are for control. The images show the adipogenic, osteogenic 
and chondriogenic differentiation ability of cryopreserved MSCs in new freezing medium.) 
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4.2.13  Effect of cryopreservation on clonogenic potential of MSCs: 
Cryopreservation may affect colony forming capacity of stem cells that results in the reduction of 
cell differentiation. In a study on controlled rate cryopreservation of UCB, it is observed that  
cryopreserved CD34+ cells contain a significant population of non-clonogenic early apoptotic 
cell which cannot be differentiated[65]. Therefore, colony-forming unit-fibroblast (CFU-F) assay 
was performed to investigate the effect of cryopreservation solution T30E30C100 on the clonogenic 
capacity of post thawed hMSCs [36]. As shown in Figure 25, non-cryopreserved MSCs 
displayed a similar CFU-F potential as observed with post thaw MSCs cryopreserved in 
T30E30C100 freezing media. The corresponding CFU-F values are measured as 11± 0.7 and 10 ± 
0.5 (SD) respectively. Furthermore, hMSCs cryopreserved in conventional 10% v/v Me2SO is 
shown to have lower colony forming capacity in comparison to hMSCs cryopreserved in 
T30E30C100 indicating the superiority of new freezing solution than the conventional one.      
 
             
Figure 25: Effect of cryopreservation on CFU-F ability of MSCs. Data represents the mean ± SD 
per 1×10
3 
cells of three separate experiments 
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5.2.14 Study on apoptosis pathways in cryopreserved induced cell death   
As already mentioned that, cryopreservation plays an important role in long term storage or 
banking of MSCs. MSCs derived from various sources are cryopreserved by slow freezing 
protocols utilizing Me2SO as cryoprotectant in freezing medium. However, it is reported that 
Me2SO fails to protect hMSCs from cryopreserved induced cell death (CICD) due to external 
stress developed during cryopreservation process. It is, therefore, essential to understand the 
mechanism of cryopreserved induced cell death using cryoprotective agents, which may be 
helpful in developing an effective cryopreservation protocol. It is further reported that the event 
of CICD is largely due to apoptosis [228]. Cryopreservation induced apoptosis is significant in a 
wide variety of cell systems including fibroblasts, hepatocytes [232], cord blood [231-232], 
peripheral blood mononuclear cells [229] renal cells [235], spermatozoa [236], oocytes and 
ovarian tissue [234]. These studies have thrown light on the molecular based cell death following 
cryopreservation and thus affecting cryopreservation outcome. It is also reported that 
manifestation of cryopreservation induced cell death may take few h to days.  However, the 
maximum apoptotic and necrotic activity occur at 24 h post thaw, following a decline in cell 
survival upto 48 h post thaw. This study of the timing of cell death following cryopreservation is 
termed as cryopreservation-induced Delayed-Onset Cell Death (CIDOCD). Previously, it has 
been observed [235] that cryoinjury induced cell death is initiated by the intrinsic or 
mitochondrial apoptotic pathway. However, according to recent report [236], both extrinsic and 
intrinsic pathways are activated after post thaw. Initiation of apoptosis after-cryopreservation has 
been shown via membrane-mediated Fas-receptor initiation by caspase-8 and caspase-9 
activation (237, 238). Studies have also shown that apoptotic pathways are activated after 
thawing that in turn activates caspases 3, 8 and 9 [239]. 
All these studies suggest that programmed cell death following cryopreservation is important to 
characterize and study. The strategy to control both membrane and mitochondrial mediated 
apoptosis pathway is essential to improve the outcome of cryopreservation procedure. The 
increase in calpain-like activity during cryopreservation is another important factor that 
influences post thaw cell survival [238-239] and the addition of calpain inhibitor results in higher 
viability rate. However, the specific role of calpain in cryopreservation induced apoptosis and 
interrelation between calpain and caspase mediated apoptosis so far remains unclear.  
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In this part of research, an attempt has been made to study the apoptosis pathways and 
mechanism for cryopreserved induced cell death. The study also investigates the extrinsic and 
intrinsic pathways as well as the involvement of calpain in the MSCs cryopreservation process.  
 
 
5.2.14.1  Post thaw cell viability 
To identify and characterize the cryopreserved induced apoptosis in MSCs, cells were 
cryopreserved with inhibitors and analyzed using flowcytometer immediately after post thaw. 
Result shows (Figure 26) that there is no significant difference in cell viability observed 
immediately after post-thaw. It is further indicated that 10% cells died during cryopreservation 
process which is independent of apoptosis. This cell death may be due to physical stress 
produced during cryopreservation process [237]. Initial cell viability result shows that all 
cryopreserved MSCs with or without pre-treatment of inhibitor have the same cell viability range 
of 85±5%. Thus the result suggests that initial cell death cannot attribute to the activity of 
caspase 3, 8, 9 or calpain.   
 
Figure 26: Effect of cryopreservation on cell viability in presence of caspase and calpain 
inhibitors. Bars represent the data from at least three experiments – standard error of the mean. 
‘Cryo’ means cryopreserved sample without inhibitor. The result shows that all the cryopreserved 
cells with or without inhibitor have same viability range of 85%±5. 
 
5.2.14.2  Caspase-mediated apoptotic signaling pathways 
One of the important characteristics of apoptosis is DNA degradation, which is thought to be a 
caspase dependent process. To compare the effect of caspase on cryopreservation induced 
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apoptosis, MSCs were incubated with various caspase inhibitors. In this study, MSCs 
cryopreserved in freezing solution shows a large population of cells with sub G0 phase (degraded 
DNA). Pretreatment of MSCs with general caspase inhibitor (z-VAD-fmk) has shown its ability 
to block the degradation of DNA, whereas pretreatment with z-IETD-fmk, z-LEHD-fmk, or z-
DEVD-fmk are not able to block DNA degradation (Figure-27 B) significantly. Furthermore to 
investigate the kinetics of cell death, cells were subjected to Annexin V/7-AAD staining to detect 
early apoptotic (Annexin V), late apoptotic/necrotic (Annexin V/7-AAD), and necrotic (7-AAD) 
cells (Figure 27). In comparison to non-cryopreserved MSCs, a signiﬁcant percentage of early 
apoptotic and late apoptotic/necrotic cells are observed when MSCs were cryopreserved in 10% 
Me2SO. However, within 24 h of post thaw, there is a significant amount (approximately 35%) 
of cell death occurs even with caspase inhibition by z-VAD-fmk. 
 
The kinetics of early, late apoptotic and necrotic cells in presence of different inhibitor treatment 
after 24h of post thaw are summarized in Figure 27. Although the pretreatment of MSCs with z-
VAD-fmk before cryopreservation is not observed to be completely protective after 24 h of post 
thaw, it inhibits the loss of cell viability significantly as compared to cryopreserved MSCs 
without inhibitor pretreatment. In marked contrast, pretreatment of these cells with selective 
caspase inhibitors such as z-IETD-fmk, z-LEHD-fmk, and z-DEVD-fmk did not have any effect 
on the loss of cell viability induced by cryopreservation. 
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Figure 27:  Effect of caspase inhibitors on cryopreservation-induced apoptosis of MSCs. (A) Untreated MSCs; (B) Cryopreserved 
sample treated with 50 mM z-LEHD-FMK; (C) Cryopreserved sample treated with 50 mM z-VAD-FMK; (D) Cryopreserved sample 
treated with 50 mM z-IETD-FMK; (E) Cryopreserved sample treated with 50 mM z-DEVD-FMK; (F) The % of viable, apoptotic, and 
necrotic cells. Bars represent the data from at least three experiments ± standard error of the mean [* indicates difference from control 
(i.e., cryopreserved MSCs without pretreatment with caspase inhibitor)]. Cryo = cryopreserved sample without inhibitor pretreatment
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5.2.14.3  Western blotting analysis of caspase proteins  
To dissect the potential role of caspases in cryopreservation-mediated MSCs apoptosis, MSCs 
were pretreated with various caspase inhibitors before cryopreservation. The aim of investigation 
is whether these caspase proteins are cleaved during cryopreservation induced apoptosis of 
MSCs, and whether this process is selectively inhibited by z-VAD-fmk, z-IETD-fmk, z-LEHD-
fmk, or z-DEVD-fmk. MSCs with or without pretreatment with caspase inhibitors were 
cryopreserved  and 24h post thaw cells were harvested for Western blot analysis using antibodies 
specific to caspases 8, 9, and 3.  
The Western blot analysis result is shown in Figure 23. The Figure shows the appearance of 
typical cleavage fragments of caspases 8, 9, and 3 proteins in cryopreserved MSCs with and 
without treatment with caspase inhibitors except z-VAD-fmk. To determine the potential 
involvement of the death receptor pathway in cryopreserved-induced apoptosis, we also 
examined the activity of Bid protein. It has been reported that Bid relays the apoptotic signal 
from the cell surface to the mitochondria. Furthermore, after cleavage due to apoptosis, truncated 
Bid translocates into mitochondria and disrupts the mitochondrial membrane potential, thereby 
triggers cytochrome c release [255]. Cryopreservation also induces activation of Bid as evident 
from Figure 28. It is observed that 32 kDa-band represents the precursor of caspase-3 while two 
smaller bands of 17 kDa and 12 kDa indicate the active subunits. A signiﬁcant decrease in 
amount of caspase-3 precursor (32 kDa) in cryopreserved MSCs is observed in presence of z-
DEV-fmk caspase inhibitor. Whereas a signiﬁcant increase in caspase-8 (18 kDa) activity is 
observed in MSCs cryopreserved in presence of other inhibitors. Moreover, the general caspase 
inhibitor (z-VAD-fmk) tends to decrease the expression of caspase proteins to a non-detectable 
level. Result also shows that z-VAD-fmk is able to significantly decrease the level of caspase-9 
precursor. Other than z-VAD-fmk, there is no signiﬁcant alteration of caspase-9 precursor in 
MSCs cryopreserved with other apoptotic inhibitors observed. Cryopreservation induces the 
activation of the initiator caspases 8, the effector caspase 3 and the pro-apoptotic protein Bid. 
Caspase 9 is activated by release of cytochrome c from the mitochondria, which causes the 
formation of the apaf-1/caspase 9 apoptosome. Caspase 8 is cleaved and activated during the 
formation of the DISC at the plasma membrane. Caspase 3 is normally in the cell as an inactive 
zymogen, where it is cleaved by initiator caspases such as 8 and 9 [26]. 
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However, the result shows that neither caspase 8/caspase 3 nor caspase/tBid/mitochondria 
pathway is solely responsible for cryopreserved induced MSCs cell death as both proteins from 
both the pathways are activated. 
 
Figure 28: Effect of cryopreservation on activation of caspase and Bid proteins. Actin has been used 
as housekeeping marker protein. Bars represent data from at least three experiments – standard 
error of the mean. C = cryopreserved sample without inhibitor pretreatment; D= cryopreserved 
sample treated with 50 mM z-DEVD-FMK inhibitor; I = cryopreserved sample treated with 50 mM 
z-IETD-FMK; L = cryopreserved sample treated with 50 mM z-LEHD-FMK; V= cryopreserved 
sample treated with 50 mM z-VAD-FMK. 
 
5.2.14.4  Mitochondrial membrane potential 
The mitochondrial or intrinsic pathway is considered to be one of the two predominant signaling 
cascades leading to apoptosis and many studies have described the depolarization of the 
mitochondrial membrane as an important characteristic of this pathway [245, 246]. Further, 
mitochondrial membrane depolarization is associated with release of cytochrome c and 
subsequent activation of caspases 9 and 3 [247]. To examine whether cryopreservation induced 
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apoptosis of MSCs involves any loss of mitochondrial membrane potential, a dual-fluorescent 
dye JC-1 was used. When the mitochondrial membrane depolarizes during cell death the dye 
dissociates into its monomeric form, which fluoresces at 530nm. In this study, the monomer vs. 
aggregate fluorescence plots (Figure 29 (A)) indicates a loss in aggregate fluorescence and an 
increase in monomer fluorescence representing a decrease in mitochondrial membrane potential. 
Interestingly, z-VAD-fmk, z-IETD- fmk, z-LEHD- fmk, z-DEVD-fmk caspase inhibitors has 
shown to significantly inhibit the loss of mitochondrial membrane potential caused by 
cryopreservation.  
 
Figure 29: Effect of caspase inhibition on cryopreserved-induced mitochondrial membrane 
potential and DNA degradation in MSCs after 24 h of post thaw (A) Bar graphs showing the 
percentage of depolarized MSCs for cryopreserved MSCs with and without caspase inhibitor and 
(B) the corresponding percentage of MSCs with degraded DNA. “Cryo” means cryopreserved 
sample without pre-treatment with any inhibitor. Bars represent data from three separate 
experiments ± standard error of the mean 
 
5.2.14.5  Calpain activity  
Calpain is a calcium-dependent neutral protease and is reported in initiating or progressing the 
events associated with apoptosis causing cell death during cryopreservation [251]. So in this 
study, the effect of calpain with and without calpain specific inhibitor (PD150606)) were 
investigated in apoptosis induced cell death during cryopreservation of MSCs. The choice of 
PD150606) as an effective calpain inhibitor is based on the published literature [252]. 
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To study the effect of calpain inhibitor on cell cycle, MSCs were pretreated with calpain 
inhibitor before cryopreservation. Result shows the significant inhibition of DNA degradation by 
the addition of calpain inhibitor (Figure 30 B). To examine the effect of calpain inhibitor on post 
thaw, MSCs were assessed by Annexin V assay for determining viable cells, apoptotic cells and 
necrotic cells. From the results it is indicated that, the presence of calpain inhibitor does not 
show any significant improvement in cell viability. However the addition of general caspase 
inhibitor (z-VAD-fmk) and calpain inhibitor (PD150606) in combination improve the cell 
viability upto 80±2%. Thus the result suggests that cryopreserved induced apoptosis is attributed 
by both caspase dependent and caspase independent.   
 
Figure 30: Effect of caspase inhibitors on cryopreservation-induced apoptosis of MSCs. (A) 
Untreated MSCs; (B) Cryopreserved MSCs treated with 50 mM z-LEHD-FMK; (C) Cryopreserved 
MSCs treated with 50 mM z-VAD-FMK; (D) Cryopreserved MSCs treated with 50 mM z-IETD-
FMK; (E) Cryopreserved MSCs treated with 50 mM z-DEVD-FMK; (F) denotes  %  viable, 
apoptotic, and necrotic cells. Bars represent the data from at least three experiments – standard 
error of the mean, [* indicates difference from control (i.e., cryopreserved MSCs without 
pretreatment with caspase inhibitor)]. ‘Cryo’ means cryopreserved sample without inhibitor.The 
flowcytometric analysis shows that cryopreserved induced apoptosis is attributed bt both caspase 
dependant and caspase independent. 
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5.2.14.6  Western blotting analysis for calpain protein 
The Western blot analysis has revealed that (Figure 31) the expression of calpain increases in 
cryopreserved MSCs and addition of calpain inhibitor decreases the cleavage of calpain protein. 
It is also observed that the addition of pan caspase inhibitor does not have any effect on 
expression of calpain protein. Interestingly, the addition of both calpain and general caspase 
inhibitor (z-VAD-fmk) has shown synergistic effect in lowering the expression of calpain. This 
result suggests that the general caspase inhibitor is not able to inhibit calpain dependant pathway. 
Also caspase and calpain mediated cell death pathways are interconnected. 
 
Figure 31: Effect of calpain inhibitor PD150606 on activation of m-calpain proteins. Cryopreserved 
MSCs were investigated after pretreatment with PD150606 with or without z-VAD-FMK. Bars 
represent data from three separate experiments– standard error of the mean. ‘Cryo’ means 
cryopreserved sample without inhibitor. PD150606 =MSCs pretreated with 50 mM PD 150606; z-
VAD-FMK=MSCs pretreated with 50 mM z-VAD-FMK; PD150606 and z-VADFMK=MSCs 
pretreated with a combination of 50 mM PD150606 and 50 mM z-VAD-FMK.The result shows that 
the general caspase inhibitor is not able to inhibit calpain dependent pathway 
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5.2.14.7  Effect of calpain inhibitor on mitochondrial membrane potential and DNA  
               degradation 
 
The experimental result of the influence of calpain inhibitor is shown in Figure 32A. Calpain 
inhibitor (PD150606) did not show any significant effect in mitochondrial membrane potential 
(MMP) during cryopreservation. However, the combination of PD150606 and z-VAD-fmk 
significantly maintained the mitochondrial membrane potential (MMP) and decreased the 
amount of DNA degradation in post thaw MSCs. These data suggest that the apoptotic signaling 
to the mitochondria has both caspase dependent and independent components. And the calpain 
dependent pathway also works through mitochondrial pathway. 
 
Figure 32: Comparative confocal images (F-actin) of cryopreserved and non-cryopreserved silk 
nanofiber TECs. (A) (i) Shows noncryopreserved TECs (control), (ii and iii) shows TECs 
immediately after cryopreservation with scale bar 5µm, (B) 24 h after cryopreservation with scale 
bar 5 µm and (C) close-up images of actin cytoskeleton 48 h after cryopreservation (ii) with scale 
bar 40 µm. In both Me2SO and T30/E30/A100/I cryopreserved groups, the cytoskeleton in the 
frozen/thawed regions is damaged, with shortened extensions and less number of cells compare to 
noncryopreserved cells. In  Me2SO frozen group, the cells have condensed, distorted after freezing, 
and less damage is observed in T30/E30/A100/I groups. 
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 5.2.15Optimization of Controlled rate freezing parameters for   
 cryopreservation of hMSCs using T30E30C100 freezing medium 
 
It is fact that depending on the type of cells and freezing media, there is need to maintain an 
optimal condition that offers maximum cell recovery following cryopreservation. In this context, 
incubation temperature, freezing medium, cooling rate, storage temperature, cell concentration 
during freezing, and duration of storage, are some of the key factors that has great influence on 
the cryopreservation outcome. while a few studies have examined the influence of freezing 
conditions on post thaw viability of MSCs using Me2SO as cryoprotectant [41, 44], no such 
study has been reported so far for optimization of cryopreservation conditions of MSCs using 
combination of cryoprotectants. Keeping this in view, efforts has been given in this section to 
investigate the effect of key controlled rate freezing parameters on cryopreservation of MSCs 
and establish the optimum cryopreservation condition using the most effective freezing medium 
T30E30C100 in presence of general caspase and calpain inhibitors. 
 
5.2.15.1 Effect of cooling profile on MSCs viability  
 
The cryopreservation experiment was carried out at different prenucleation cooling rate such as-
1ºC/min, 2.5ºC/min, 5ºC/min and 10ºC/min to examine the effect of prenucleation cooling rate 
on cell viability. The others parameters such as: nucleation temperature (-7.5°C), cold spike 
temperature (-40°C), hold time (10min), and post nucleation cooling rate (1°C) were maintained 
constant. The parameters were chosen based on published literature [143]. As shown in Figure 
33a, the effect of prenucleation temperature is shown to have a significant influence on cell 
viability. The cell viability increases with decrease in cooling rate. The maximum cell viability 
of 82% is obtained at prenucleation cooling rate of -1.0°C/min. Comparable cell viability is also 
achieved at -2.5°C/min.  
Similarly, the effect of nucleation temperature (-2.5°C, -5°C, -7.5°C and -10°C) on cell viability 
was studied and the experimental result is shown in Figure 33b. The highest cell viability of 78% 
is achieved at nucleation temperature of –7.5°C and a decline in cell viability is observed with 
either higher or lower than –7.5°C nucleation temperature. The others parameters such as: 
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prenucleation cooling rate 1°C/min, cold spike temperature (-40°C), hold time (10min), and post 
nucleation cooling rate (1°C) were maintained constant.  
The effect of shock cooling or so called cold-spike temperature on cell viability was investigated 
by performing cryopreservation experiment at varying shock cooling temperature in the range of 
-20°C, -40°C, -60°C and -80°C. Figure 28c shows the effect of shock cooling temperature on 
MSCs recovery. The optimal cell viability was recorded as 85% at -80°C. The others parameters 
such as: prenucleation cooling rate 1°C/min, nucleation temperature (-7.5°C), hold time (10min), 
and post nucleation cooling rate (1°C) were maintained constant.  
Figure 33d shows the effect of different holding times at post-nucleation temperature of -30°C. 
An upward trend of cell viability is observed till holding time 10min is reached and there is 
decrease in cell viability observed beyond this holding time. The optimal cell recovery of more 
than 80% is obtained with 10min holding time.  
Finally, Figure 33e shows the effect of post nucleation cooling rate on post thaw cell viability. A 
decrease in cell viability is observed over the range of cooling rate tested and the post nucleation 
cooling rate of 1°C/min offers the maximum cell viability (84%) results. The others parameters 
such as: prenucleation cooling rate 1°C/min, nucleation temperature (-7.5°C), and holding time 
(10min) were maintained constant. 
Our results demonstrate the sensitivity of cell viability to the cooling profile used during 
cryopreservation in controlled rate freezing. However, the optimized cooling profile is 
establishes as prenucleation cooling rate 1
o
C/min, nucleation temperature -7.5
o
C, cold spike of 
80
o
C/min, post nucleation holding time of 10min and post nucleation cooling rate of 1
o
C/min. 
The resultant optimum cooling profile is shown in Figure 34.  The results from the controlled 
rate freezer (CRF) temperature control study, illustrating the process temperature profiles for 
sample in the CRF chamber with cold-spike nucleation control over the period of a 
cryopreservation study. A blue line indicates the temperature profile of the chamber in response 
to a programmed profile for freezing hMSCs. The typical cooling profile included five steps: (1) 
equilibrate temperature, (2) induce ice formation with a cold spike, (3) warming rate, (4) hold at 
–35 °C for 10 minutes, and (5) cool to –40 °C at a cooling rate of 1.0 °C/min. The uniformity of 
nucleation is apparent right after the cold gas was plunged to –80 °C, as shown in the figure 
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temperature profiles of sample and chamber were tightly aligned together through the whole 
freezing process. Optimization of cooling profile has been carried out based on the sample 
temperature.  
 
 
Figure 33: Percentage recovery of MSCs after cryopreservation in controlled rate freezer under 
different cooling variables (a) pre-nucleation cooling rate in °C/min (b) prenucleation temperature 
in °C; (c) cold-spike temperature in °C/min; (d) holding time in min(e)  post nucleation cooling rate 
in °C/min 
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Figure 34: Temperature profile of cryochamber and sample with time; blue line represents the 
chamber temprature, green line represents the sample temperature. (a) equilibrium temperature; 
(b) a pre-nucleation cooling step; (c) a pre-nucleation temperature step; (d) a cold spike step; (e) a 
post-nucleation temperature hold step and (f) a final cooling step. 
 
5.2.15.2 Effect of cell density  
The cryopreservation experiment was designed to test whether cell concentration has any effect 
on cell viability following cryopreservation. Study has shown that increase in cell concentration  
decreases cell viability and metabolic activity in hepatocytes [70]. During slow cooling, ice 
formation mainly occurs on extracellular spaces but as the cell concentration increases 
extracellular spaces are decreased by cell packing due to which intracellular ice formation occurs 
more readily. In this study the varying concentration of MSCs such as 0.5, 1, 2, 3, 4 and 
5×10
6
/ml were investigated to establish optimal concentration to maximize cell viability. The 
cell viability results of post thawed MSCs are shown in Figure 35. Each set of experiment was 
performed in triplicate. An unpaired t-test was conducted taking 3×10
6
/ml MSCs as control. The 
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result indicates that the maximum cell recovery is achieved with 3×10
6
/ml followed by 
2×10
6
/ml. Furthermore, a decrease in cell viability is observed with increase in cell concentration 
beyond 3×10
6
/ml.   
 
Figure 35: Effect of cell concentration on cell viability 
5.2.15.3  Effect of storage temperature  
Recent study suggests that storage temperature plays an important role in cell viability [91-102]. 
So, the effect of different storage temperature such as −80°C, −150°C and −180°C has been 
studied on the cell viability. The different storage temperatures were chosen based on the 
published literature [66-69]. The experimental data of MSCs viability after cryopreservation is 
shown in Figure 36. Result shows that cell viability significantly varies with storage temperature 
from -80°C to -150°C. However the maximum cell viability is achieved at -150°C and then a 
decline in cell viability. is observed 
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Figure 36: Effect of different storage temperature on cryopreserved MSCs  viability 
5.2.15.4  Verification of cryopreservation protocol  
5.2.15.4.1  Effect of cryopreservation on cytoskeleton and mitochondria distribution  
As it is mentioned earlier, F-actin has a role in controlling cell morphology and surface 
movement [120] as well as cellular functions [121-124]. It is reported that the critical factor that 
changes F-actin morphology and distribution is not associated with addition or removal 
cryoprotectant but freezing profile [123]. Result shows (Figure 37) that at the optimum 
controlled rate of freezing (CRF) condition F-actin shows a better maintenance recovery in 
morphology and distribution of cytoskeleton in cryopreserved MSCs than that of the cells 
cryopreserved using uncontrolled rate of freezing using mechanical freezer. The result also 
confirms the organization of cytoskeletons of cryopreserved MSCs is similar to the non-
cryopreserved MSCs. The quantitative and morphological alterations in the mitochondrial 
potential were detected using JC-1, a fluorescent probe [125]. Result shows that there is no 
significant changes in mitochondria fluorescence in cryopreserved MSCs at optimum condition 
compared to non cryopreserved MSCs (as negative control) shown in Figure 37.  
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Figure 37: Fluorescence images of F-actin and mitochondria distribution in fresh and cryopreserved hMSCs. Scale bar: 100µm
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5.2.15.4.2  Cell cycle and viability analysis 
Cell cycle analysis was performed to determine the cell phase after cryopreservation (Figure 38). 
The results indicate that both non cryopreserved and cryopreserved MSCs at optimum controlled 
rate freezing condition show similar trend with highest percentage of cells in G0/G1 as compared 
to, S and G2/M which signify that most of the cells are active and proliferating (Figure 38). 
Analysis of cell cycle indicates that the cryopreserved MSCs are in 78% G0/G1; 4.67%G2/M; and 
6.43% S phases (Figure 38B). The average viability is calculated based on flowcytometry is 
85%. 
 
 
Figure 38: Cell cycle analysis of (A) non-cryopreserved MSCs and (B) Cryopreserved MSCs 
Comparison of the freezing solution  
A comparison of the efficiency of freezing solutions for the cryopreservation of MSCs has been 
shown in Table 11. It is indicated that after 12 months of cryopreservation 10% v/v Me2SO 
shows the lowest viability.  Further an increased viability of T30/E30/C100/I was obtained with 
addition of apoptotic inhibitors .and the highest MSCs viability is shown by T30/E30/C100/I at 
optimum controlled rate freezing condition  
 
 
 
A B 
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Table 11: Comparison of cell viability of cryopreserved MSCs in T30E30C100 solutions and Me2SO 
after 12months of storage 
Sl. No. Freezing solution Conditions Viability 
1 10% v/v Me2SO  Control rate 
freezing (1ºC/min)  
    61% 
2 Trehalose (30mM), ectoin (30mM), catalase 
(100µg) 
Control rate freezing 
(1ºC/min) 
    73.6% 
3 Trehalose (10mM), ectoin(5mM), catalase 
(100µg) with pan caspase (50µM) and calpain 
inhibitor (50µM) 
Control rate freezing 
(1ºC/min) 
    80% 
4 Trehalose (10 mM), ectoin (5mM), catalase 
(100µg) with pan caspase (50µM) and calpain 
inhibitor (50µM) 
Control rate freezing 
at optimized 
condition  
    85% 
 
Conclusion 
The main aim of the study in this phase was to explore potential natural CPA or a combination 
these CPAs to formulate an effective freezing solution towards preservation of MSCs by a 
controlled rate freezing method. The combination of CPAs used under study has shown better 
performance than the individual one as well as the traditional 10%v/v DMSO. Among the CPAs 
combinations, freezing solution consisting of trehalose, ectoine and catalase is found to be the 
most effective. Furthermore, from the cryopreservation study on the freezing solutions prepared 
from a different composition of trehalose, ectoin and catalase,  the freezing solution with trehalose 
(30mM ectoin (30mM) and catalase (100µg) has shown optimum composition achieving 
maximum cell viability. The viability of cryopreserved MSCs was further improved by the 
addition of apoptotic inhibitors, the most effective of which are calpain PD150606 (50µM) and 
caspase z-VAD-fmk (50µM) inhibitors. This freezing solution has exhibited maximum post thaw 
survival with retention of cytoskeleton, membrane potential, rate of proliferation and 
differentiation ability. Furthermore, the optimum condition for the controlled rate freezing of 
MSCs was established as prenucleation cooling rate 1
o
C/min, nucleation temperature -7.5
o
C, cold 
spike 80
o
C/min, post nucleation holding time 10min and post nucleation cooling rate 1
o
C/min. and 
the maximum cell viability obtained at optimum condition is 85% as shown in Table 11.  
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PART II  
Cryopreservation of hMSCs seeded silk nanofibers 
based tissue engineered constructs 
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As it is described in previous chapter that because of the possibility of autologous and non-
tumorogenic characteristics, MSCs has been used as an attractive cell source in recent research 
focusing on the development of various tissue engineered constructs (TECs) to repair defect 
and/or diseased tissues and organs.  In view of the emerging demand of these tissue engineered 
products, the development of an effective preservation technique is of paramount importance for 
the potential future applications of these tissue constructs clinically.  
Besides cell source, the development of an artificial extra cellular matrix so called scaffold from 
biodegradable and biocompatible biopolymers is another important aspect in tissue engineering.  
Among the various biomaterials, silk fibroin (SF) extracted from silkworm cocoons possesses 
suitable surface, remarkable mechanical and desired biological properties that can mimic the 
human bone and other tissue and thus is considered as a potential candidate for the development 
of TECs using MSCs [71] . 
Therefore, in this phase of dissertation work, the performance of the best freezing medium 
consisting of the combination of trehalose, ectoin and catalase (T30/E30/C100/I) was evaluated 
towards the preservation of MSCs seeded SF scaffold (TECs) and the optimum control rate 
freezing condition was established. 
5.3.1 Structural integrity and cell morphology in TECs 
The crypreservation strategy has to be designed in such a way that it must be able to preserve the 
constructs on long term basis without affecting any structural integrity of the scaffold and maintain 
the membrane integrity of the cells in TEC.  It is reported that the maintenance of structural integrity 
of the scaffold is a prerequisite in cryopreservation of cell–biomaterial constructs. Any deformation 
in the scaffold during cryopreservation may affect cell functionality. It was, therefore, investigated 
whether the cryopreservation had any adverse effect on the scaffold structure and morphology of 
MSCs in TECs by SEM study. SEM images (Figure 39, 40) of scaffolds and TECs before and after 
cryopreservation were generated on 1 and 14 days of culture. As indicated in Figure 37, no visible 
structural deformity on the surface of the nanofibrous scaffolds with (Figure 39) and without seeded 
MSCs (Figure 39) as well as before and after cryopreservation are observed. Furthermore, while 
comparing the type of freezing medium used for cryopreservation such as Me2SO and combination 
of natural osmolytes (T30/E30/C100/I), TECs cryopreserved in T30/E30/C100/I freezing solution have 
shown better MSCs attachment and spreading than Me2SO as evident from Figure 40. This enhanced 
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cell attachment may be due to less mass transfer impedance, uniform heat distribution and desired 
pore size of scaffold that facilitated the penetration of cryoprotectant as reported earlier [256]. 
Furthermore, no signiﬁcant morphological difference of MSCs was observed between non-
cryopreserved and cryopreserved TECs. This signifies that the microcellular environment of the 
MSCs in nanofiber scaffold used in this study remain unaltered in post thaw TECs. Thus it has been 
established that T30/E30/C100/I is an effective freezing medium for TECs preservation in terms of 
maintenance of structural integrity of scaffold and retention of cell morphology during 
cryopreservation process.   
 
 
Figure 39:SEM images of (A) noncryopreserved and (B) cryopreserved scaffold. Scale bar: 5µm 
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Figure 40: SEM images of cryopreserved scaffold (A) precryopreserved constructs after 1 day, (D) precryopreserved constructs after 
14th days , (B) Cryopreserved constructs using freezing solution T30/E30/C100/I after 1 day, (E) Cryopreserved constructs using freezing 
solution T30/E30/C100/I after 14days, (C) Cryopreserved constructs using freezing solution Me2SO after 1 day and (F) Cryopreserved 
constructs using freezing solution Me2SO after 14 days. Scale bar: 10µm 
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5.3.2 MSCs viability  
The MSCs viability in cryopreserved TECs was assessed using flowcytometry analysis by 
determining the percentage of post thaw necrotic cells. As shown in Figure 41, the cell viability 
in TECs is obtained as 54.37±2.1% using 10% Me2SO, 72.5± 1.8% with T30/E30/A100/I freezing 
solutions and 95±2% with non-cryopreserved MSCs. Among the various freezing medium, the 
maximum cell viability was achieved with T30/E30/C100/I freezing solution. Furthermore, result 
shows that CPAs containing trehalose/ ectoin/catalase with or without apoptotic  inhibitors have 
better cell viability than the standard 10% Me2SO solution which is statistically signiﬁcant 
(p=0.0003 and 0.0021). Furthermore, the cell viability of non-cryopreserved and cryopreserved 
TECs groups showed statistically signiﬁcant differences, the higher MSCs viability is obtained 
with the former, which is obvious. The cell viability results were further confirmed by MTT 
assay. 
 
 
Figure 41: Cell viability after 24h of post thaw TECs in different freezing solution and 
noncryopreserved MSCS. Bar represents standard deviation (n = 3) 
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5.3.3  Proliferation assay 
The metabolic activity of MSCs seeded on SF scaffolds after post thaw was evaluated by MTT 
assay and the result is shown in Figure 42. It is observed that the metabolic activity of the cells 
on the scaffold cryopreserved in T30/E30/A100/I is signiﬁcantly higher than the TECs 
cryopreserved in 10% Me2SO (*p value > 0.05and **p value > 0.005). The result has shown 
similar trend as the cell viability results obtained by flowcytometry analysis as presented in 
previous section.  
 
Figure 42: MTT assay of the metabolic activities of post thaw MSCs seeded on SF scaffolds. 
Result demonstrates statistical differences between l0%v/v Me2SO (control) and T30/E30/C100/I 
freezing solution after 3, 5 and 7 days (n = 3; ∗p < 0.05; ∗∗p < 0.01) 
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5.3.4  Cytoskeleton analysis 
Organization of F-actin, largely determines the cellular morphology and surface movement [256, 
257]. Because of their close proximity, any mechanical damage to the membrane might also 
disrupt the F-actin. During cryopreservation, extracellular ice, mechanical stress and differential 
thermal contraction between cells and substrates occur that may cause depolymerization and 
accumulation of F-actin. Cytoskeleton integrity plays a major role in cell viability, cell 
proliferation and differentiation. Loss of function of cell membranes interferes with transport 
systems such as pH regulatory systems on the cell membrane. Disruption of organelle 
membranes affects transport systems such as mitochondrial transport systems that is essential for 
oxidative phosphorylation, the major energy-generating pathway [258-259] Therefore, 
cytoskeleton integrity of TECs was assessed by confocal microscopy and confocal images are 
shown in Figure 43. The investigation on the effect of cryopreservation on the organization of F-
actin has shown no remarkable impact on F-actin of MSCs in TECs by cryopreservation using 
T30/E30/A100/I. Whereas significant distortion of F-actin, ruptured membrane, low intensity of 
stress fiber and unclear boundary are observed with cryopreserved TECs using Me2SO. 
 It is further observed that the noncryopreserved TECs has retained its cell morphology as 
represented by the existence of intact cell membrane. Immunofloroscence has shown better cell 
attachment in TECs cryopreserved in T30/E30/A100/I compared to the cell attachment using 
Me2SO. However, cell attachment is lower than that observed with unfrozen TECs in all the 
cases.  
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Figure 43: Comparative confocal images (F-actin) of cryopreserved and non cryopreserved silk nanofiber TECs. (A) (i) Shows 
noncryopreserved, (ii and iii) shows the TECs immediately after cryopreservation with scale bar 5 lm, (B) 24 h after cryopreservation 
with scale bar 5 mm and (C) close-up images of actin cytoskeleton 48 h after cryopreservation (ii) with scale bar 40 µm. In both the 
Me2SO and T30/E30/A100/I groups, the cytoskeleton in the frozen/thawed regions is damaged, with shortened extensions and less number of 
cells compare to noncryopreserved cells. In the Me2SO frozen group, the cells have condensed, distorted after freezing, and less damage is 
observed in T30/E30/A100/I groups. 
Results & Discussion 
 
 
5.3.5 Alkaline Phosphatase activity  
The ALP activity of MSCs on the nanoﬁbrous scaffolds up to 21 days culture in osteogenic 
differentiation media is shown in Figure 44. The study shows the increase in ALP production 
progressively on cryopreserved and non cryopreserved TECs indicating the osteoblastic 
differentiation ability of MSCs on scaffold. Additionally, a highly signiﬁcant difference (p < 
0.05) in ALP  production is observed between Me2SO and T30/E30/C100/I. Overall, an increase in 
ALP activity from 8±0.9µg to 4000±67µg and 9±0.3µg to 3848±400 with cryopreserved TECs 
in Me2SO and T30E30C100/I   are achieved during 1 to 21 days of culture period.  
 
Figure 44: ALP activity was studied on day 1, 7 and 21 of post thaw MSCs cultured on silk 
nanofiber scaffolds in freezing solution of 10% Me2SO and T30/E30/A100/I as evaluated by NBT 
substrate in osteogenic induction medium. Results shows significant difference (p > 0.05) in ALP 
activity after 7 and 14 days post thaw culture. 
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  5.3.6  Effect of cryopreservation on Mechanical properties of TECs 
In tissue engineering, scaffold must have desired mechanical properties which become critical 
when it is used for bone tissue regeneration in particular. During cryopreservation, the 
mechanical strength of scaffold may be altered due to the occurrence of thermal stress[75-76]. 
Therefore, mechanical test was performed on cryopreserved and non cryopreserved TECs to 
investigate the effect of cryopreservation on tensile strength of scaffold. Statistical analysis 
indicates that, tensile strength of the non-cryopreserved, TECs cryopreserved in Me2SO and 
T30/E30/C100/I were 1.82 ±0.31Mpa, 1.35±0.19Mpa and 1.79 ±0.21Mpa respectively (Figure 45). 
Furthermore, no significant difference was observed between non-cryopreserved and 
cryopreserved TECs in T30/E30/C100/I. It has been assessed that the combined CPA T30/E30/C100/I 
did not show any remarkable effect on the mechanical property of the scaffold. However, the 
tensile strength of the scaffold decreases significantly with Me2SO preserved TECs. Similar 
result is also reported in another study [15]. Thus it is established the superiority of T30E30C100/I 
over Me2SO as freezing solution. 
 
Figure 45: Ultimate tensile strength of TECs cryopreserved in T30/E30/C100/I, Me2SO and 
noncryopreserved TECs (Fresh) 
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5.3.7 Calcium deposition  
The effect of cryopreservation on the osteogenic differentiation capacity of MSCs in TECs was 
investigated qualitatively by histological staining of calcium deposition on the scaffold. As 
shown in Figure 46 and 47, MSCs are found to attach and spread throughout the scaffolds. A 
network of cells and ECM with a relatively small amount of granular deposition of calcium is 
covered on the scaffold surface when TECs is cryopreserved in Me2SO. Whereas, a higher 
deposition of calcium is observed with noncryopreserved and cryopreserved T30/E30/C100/I TECs 
indicating the higher degree of osteogenic activity of MSCs. SEM results indicated the MSCs 
remained adhered to the scaffold and mineralization structures intact (Figure 47). EDXA 
detected the presence of phosphorus and calcium confirming the presence of mineralized 
structures (Figure 47 B and D). 
 
Figure 46: Optical images of alizarin red staining for calcium deposition of osteogenically induced 
MSCs in post thaw TECs (A) TECs without osteogenic media (B) TECs with osteogenic media 
without cryopreservation, (C) TECs cryopreserved in Me2SO (D) TECs cryopreserved in 
T30/E30/C100/I. Scale bars represent 50 mm  
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Figure 47: SEM and EDX analysis of post-thaw TECs cultured in osteogenic differentiation 
medium for 21 days -(A) TECs cryopreserved in T30/E30/C100/I, (C) TECs cryopreserved in 10% 
Me2SO, (B) and (D) depicts the EDX analysis of the elemental components of calcium phosphate 
salts, consisting of P, Ca and O elements in both groups scaffolds 
 
5.3.8  Expression of osteogenic-speciﬁc genes 
The quantitative osteogenic differentiation level of seeded MSCs on TECs was assessed by 
quantitative PCR of bone-speciﬁc genes. From the analysis of Figure 48, the osteogenic 
differentiation genes such as collagenase-1[Col 1], core binding protein [Cbfa 1], osteocalcin 
[OCN] and alkaline phosphate [APL] are observed to be increasingly expressed on T30/E30/C100/I 
cryopreserved group during 14 day of culture in comparison to Me2SO cryopreserved groups.  
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Figure 48: Osteogenic gene expression levels of post thaw MSCs in TECs cultured in osteogenic 
media 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
120 | P a g e  
 
5.3.9  Optimization of controlled rate freezing parameters for preservation of 
TECs using T30/E30/C100 freezing medium 
 In this section, it was further investigated the effect of key controlled rate freezing parameters 
on cryopreservation of TECs and establish the optimum cryopreservation condition using the 
most effective freezing medium T30/E30/C100/I  in presence of apoptotic inhibitors. 
5.3.9.1  Effect of cooling rate on MSCs viability in TECs 
The effect of cooling rate (-0.5°C/min, -1.0°C/min, -2.5°C/min, -5°C/min and -10°C/min) on 
MSCs viability was studied and the experimental result is shown in Figure 49. As it is indicated 
the highest cell viability of 74% is achieved at cooling rate of -1.0°C/min and a decline in cell 
viability is observed with either higher or lower than -1.0°C/min cooling rate at constant seeding 
temperature of -7.5 °C  
 
Figure 49: Effect of different cooling rate on MSCs seeded TECs 
 
5.3.9.2  The effect of seeding temperature on cell viability 
The effect of seeding temperature on cell viability was investigated by performing 
cryopreservation experiments at varying seeding temperature at -5 °C, -7.5 °C and -10°C. The 
optimal cell viability was recorded as 80 % at -7.5 °C seeding temperature. The rate of cooling 
temperature is maintained constant at1°C /min. 
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Figure 50: Effect of seeding temperature on MSCs seeded TECs 
5.3.9.3 Cell Morphology  
After cryopreservation of MSCs seeded scaffold, the cell population was observed to be 
decreased in comparison to fresh unfrozen MSCs, representing that cryopreserved induced stress 
resulted in cell detachment as shown in Figure 51. Furthermore, more number of cells is 
detached in 5°C/min and 10°C/min rate cryopreserved cells in comparison to the cells 
cryopreserved at 1°C/min. SEM result reveals that before cryopreservation, the adherent hMSCs 
were in spindle shape. But after cryopreservation at 5 and 10°C/min, the cells did not maintain 
their original shape, either in flatten shape or round shape. Moreover, the cell number becomes 
less after cryopreservation at the cooling rates of 5 and 10 C/min than the fresh MSCs. 
.
Results & Discussion 
 
 
 
Figure 51: SEM images of TECs under different cooling rate and seeding temperature 
Results & Discussion 
 
 
Conclusion 
From this study, it is established that T30/E30/C100/I  is found to be an effective freezing medium 
in preserving TECs developed from hMSCs and nanofiberous SF scaffold as confirmed by the 
cell viability, proliferation and differention ability of hMSCs in TECs after and before 
cryopreservation. Furthermore, an enhanced cell vitality of of MSCs is obtained by optimizing 
the controlled rate freezing parameters. The optimum cryopreservation condition was established 
s cooling rate of 1
o
C / min and nucleation temperature of -7.5
o
 C giving maximum cell viability 
of 80%. 
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SUMMARY & CONCLUSION 
                  
  
In recent years, mesenchymal stem cells (MSCs) and MSCs derived tissue engineered constructs 
(TECs) have been considered as important biological products that can be used for a variety of 
therapeutic and tissue engineering applications including bone, cartilage, tendon, muscles, blood 
vessel and other tissue regeneration. Therefore, recent research is directed towards the production 
of MSCs and MSCs seeded tissue engineered constructs (TECs) to repair defect and/or diseased 
tissues and organs. However, the successful clinical applications of these cells and tissue 
engineering products rely on the development of an appropriate cryopreservation technology that 
offers long time storage of such products with desired cell viability, metabolic activity and cellular 
differential ability. Me2SO a traditional freezing solution is currently used for preservation of 
various cells and other biological species. However, freezing protocol using Me2SO as 
cryoprotecting solution is reported to have several detrimental effects on the cryopreserved cells 
and hence harmful to patients.  
In this context, a combination of a variety of natural osmolytes seems to be effective 
cryoprotective agents in preserving MSCs and other cells. Furthermore, it has been reported that 
the controlled rate freezing technology is superior to the uncontrolled freezing methods of 
preserving cells. However, no systematic research effort has so far been given to develop an 
efficient cryopreservation strategy for long term preservation of MSCs and TECs using natural 
osmolytes. Therefore, the present dissertation work has been undertaken to develop a 
cryopreservation strategy using a freezing medium consisting of natural cryoprotective agents that 
can be useful for the long term preservation of MSCs and MSCs seeded tissue engineered 
constructs. 
The major outcome achieved through this research work is summarized as follows- 
I. In the first phase of the dissertation work, a variety of natural cryoprotective agents in 
combination were investigated to see their ability towards cryopreservation with the aim of 
developing an effective freezing medium that can be useful for preserving MNCs and other cells 
like MSCs. MNCs were isolated from umbilical cord blood by Ficol hypaque technique and 
cultured. The extracellular cryoprotectants (10mM) namely trehalose, hydroxyl ethyl starch, 
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polyvinyl pyrrolidine and intracellular CPAs (5mM) like erythritol, taurine and ectoine were used 
to prepare different combinations of freezing medium following L9 (34) Taguchi orthogonal array. 
Catalase, coenzyme Q10 and n-acetyl cystine (100μg/m) were added as antioxidants. The 
cryopreservation experiments were conducted in a controlled rate freezing condition. The 
combination of extracellular, intracellular CPA and antioxidant has shown encouraging results 
towards the maintenance and survival of cell during and after freezing. Among the CPAs and 
antioxidants used under study, trehalose, ectoin and catalase have shown the best cryopreservation 
performance achieving high cell viability. The post thaw viability is also observed to be 10% 
higher than the cell viability obtained using conventional Me2SO as CPA. Furthermore, SEM and 
phase contrast microscopy confirmed the normal cell morphology of the post-thaw cultured cells 
with retaining their membrane integrity.  
 
Thus it has been demonstrated that the cryopreservation medium consisting of trehalose, ectoin 
and catalase is the most effective freezing solution that may be of further interest of research to 
design a standard cryopreservation protocol for MSCs  
 
II. In this  part of the thesis work, the most effective natural osmolytes such as trehalose and ectoin 
in presence of catalase antioxidant as obtained in the previous section were further evaluated for 
their effectiveness towards the long term preservation of much demanding MSCs for therapeutic 
and tissue engineering applications. To accomplish this task, MSCs were sorted from cultured 
MNCs by fluorescence activated cell sorter (FACS), cultured and characterised for their 
morphology, and immune-phenotype. MSCs were then subjected to controlled rate freezing using 
various freezing solutions using trehalose and ectoin as CPAs individually and in combination 
with varying ratios of trehalose and ectoin. The freezing solution containing the combination of 
CPAs has shown better post thaw cell viability than the individual CPAs as well as control 
(Me2SO). Furthermore, among various composition of CPAs tested under study, the freezing 
medium having combination of 30mM trehalose, 30mM ectoin and 100µg catalase (T30/E30/C100/I) 
exhibited maximum post thaw survival with retention of cytoskeleton, membrane potential and 
rate of proliferation. The cryopreserved MSCs have also shown the desired differentiation ability 
even after 12months of storage. It is thus concluded that T30/E30/C100 freezing solution developed 
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in this study is effective in preserving UCB derived MSCs in long term basis and the maximum 
cell viability archived was 73%.  
 
III. In this phase of research work, an attempt has been made to determine the cryopreservation 
induced apoptosis signalling pathways and evaluate the role of caspase-dependent and 
independent apoptotic pathways in MSCs. to accomplish the task MSCs were cryopreserved in a 
control rate freezer, using T30/E30/C100/I as cryoprotective agent either with or without pre-
treatment with general caspase inhibitor z-VAD-fmk, or with the more selective caspase inhibitors 
such as z-IETD-fmk, z-LEHD-fmk, and z-DEVD-fmk. Furthermore, to evaluate the effect of 
calcium mediated pathway, the cryopreserved MSCs samples were tested with and without calpain 
inhibitor. FACS was used to measure the cell viability, mitochondrial membrane potential and cell 
cycle analysis. Processing of procaspases 3, 8, 9, µ calpain and Bid was determined by Western 
blotting. Cryopreservation of MSCs resulted in characteristic apoptosis within 24 h after post 
thaw. It has been established that the addition of calpain inhibitor and pan caspase inhibitor are 
used in CPA solution increases the cell viability to 80 %. 
 
IV. In this phase of work, the cryopreservation condition was further optimised to increase the 
efficiency of the best obtained freezing solution (T30/E30/C100/I) in presence of caspase and calpain 
inhibitors. The various parameters were investigated are prenucleation cooling rate, nucleation 
temperature, cold spike temperature, post nucleation holding temperature, post nucleation cooling 
rate, cell concentration and storage temperature.  The result indicated that the cooling profile has a 
significant impact on cell viability. The optimum condition for the controlled rate freezing of 
MSCs was established as (i) Prenucleation cooling rate -1
o
C / min (ii) Nucleation temperature -
7.5
o
C (iii) Cold spike -80
o
C/min (iv) Post nucleation holding time of 5
 
min (v) Post nucleation 
cooling rate -1
o
C/min. (vi) 3×10
6
/ml cell concentration. The maximum cell viability obtained at 
optimum condition is 85%.  
 
V. In this part of the thesis, research work was further extended to evaluate the potentiality of the 
most effective freezing solution obtained in the previous section towards the preservation of TECs 
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derived by seeding of MSCs on nanofibrous silk fibroin scaffold (TECs) by conducting 
cryopreservation experiments in a controlled rate freezer. The SF scaffolds used for TECs 
formation is made from eri and tasar SF blend. To the best of our knowledge, the present study is 
the first report on the cryopreservation of MSCs-seeded nanoﬁbrous scaffold fabricated from silk 
fibroin which is considered as a promising biomaterial for tissue engineering applications. It has 
been observed from the experimental results that the viability and functionality of hMSCs on SF 
scaffolds were well maintained and cultured after cryopreservation. These are well supported by 
the assessment of cell viability (flowcytometry analysis & MTT assay), structural integrity (SEM 
and confocal images) and functionality in terms of osteogenic differentiation ability 
(Immunohistochemistry, RT-PCR analysis & ALP assay) of TECs. The newly formulated freezing 
solution of combined CPAs (T30/E30/C100/I) further did not show any adverse impact on the 
mechanical property of the scaffold in cryopreserved TECs. Thus it is established the effectiveness 
of T30/E30/C100/I as freezing medium in preserving TECs developed from hMSCs and SF scaffold.  
 
VI. In this phase of research work, an optimization study was carried out to maximise the recovery 
of MSCs on TECs cryopreserved in T30/E30/C100/I freezing medium. The effect of key controlled 
rate freezing parameters was investigated and optimum freezing condition was established as 
cooling rate of -1
o
C/min and seeding temperature of -7.5
o
C/min. The maximum MSCs viability of 
80% was achieved at optimum condition. 
 
Overall, in this dissertation work, a Me2SO free freezing solution consisting of a combination of 
natural osmolytes such as trehalose (extracellular CPA) and ectoin (intracellular CPA) with 
catalase as antioxidant has been established as an effective cryopreservation medium for long 
term preservation of MSCs and MSCs seeded on tissue engineered constructs. The efficiency of 
the freezing medium achieving high MSCs recovery can further be improved by the addition of 
apoptotic inhibitors. It is finally concluded that the development of a controlled rate freezing 
system using the freezing medium (T30/E30/C100/I)established in this study may pave the way for 
long term preservation of MSCs and MSCs seeded tissue engineered products for clinical 
applications 
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